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                              Summary 
The transport of cyclic nucleotides out of the cell is energy requiring, dependent on ATP- 
hydrolysis. The ability to stimulate this ATPase is a hallmark of substrates for ABC-
transporters e.g. ABCC5, ABCC4. It is believed that ABCC5 transporter has selective high 
affinity for cGMP. Previous studies support the idea that ABCC5 contribute to cGMP 
transport by human erythrocytes. Human erythrocyte membrane possesses cGMP transport 
system that utilizes ATP for its activity. Present study was conducted to measure, “Cyclic 
nucleotide dependent ATPase activity in inside out vesicles from human erythrocytes” by an 
In-house assay method and to compare it with commercially available kit to make cost benefit 
analysis. 
The main findings were: 1) The inorganic phosphate standard curves were linear for relevant 
biological concentrations, observed for both in-house and commercial assay. 2) The 
membrane protein (i.e. IOV) concentrations raised the inorganic phosphate concentrations 
linearly. 3) It was possible to distinguish cGMP-stimulated activity from basal ATPase 
activity in hRBC IOV, even though the difference was small. 4) The two phosphate assays 
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                              Abbreviations: 
 
 
   Abbreviation 
 
  
      Meaning    
 
    ABC-transporters 
   ABCC4 
   ABCC5 
   Abs.  
   AchE  
   AC 
   ADP 
   AMP 
   ANP 
   ATCC 
   ATP 
   ATPase 
   BC 
   cAMP 
   cGMP 
   Conc. 
   EDTA 
   EGTA 
   Exp 
   FIQ1 
   FIQ2 
  GAPD-activity 
  GPCR                   
   GTP 
   hRBC 
   IOV     
   IQ1 
  
  ATP-Binding –cassette transporters 
  Multidrug resistance-associated protein 4 
  Multidrug resistance-associated protein 5 
  Absorbance. 
  Acetylcholinesterase. 
  Adenyl cyclase. 
  Adenosine diphosphate. 
  Adenosine monophosphate 
  Atrial natriuretic peptide.   
  Acetylthiocholine-chloride. 
  Adenosine triphospahte. 
  Adenosine triphosphatase 
  Reagent B  
  Cyclic adenosine monophosphate 
  Cyclic guanosine monophosphate 
  Concentrations 
   Ethylene diamine tetraacetic acid 
   Ethylene glycol tetraacetic acid 
   Experiment 
   Final incubation #1 
   Final Incubate # 2 
   Glyceraldehyde-3-phosphate dehydrogenase 
   G protein coupled receptors 
   Guanylyltri phosphate 
   Human red blood cells 
   Inside out vesicles 










   IQ2 
   IS1 
   IV0 
   IVX 
   Mg-ATP 
   MgCl2 
   MRP4 
   MRP5 
   NO 
   OD  
    PKA   
    PDE   
    PKG  
    PGC  
    pH 
    Pi 
    RBC      
    ROV 
    SDS 
    SGC 
    Sr.# 
    Sted.Dev. 
    
    
 
   Incubation solution # 2 without cGMP 
   Incubation solution S1 
   Inside out vesicles with 0 detergent 
   Inside out vesicles with X-100.  
   ATP.magnesium salt 
   Magnesium chloride 
   Multidrug resistance-associated protein 4 = ABCC4    
   Multidrug resistance-associated protein 5 = ABCC5 
   Nitric oxide   
   Optical Density. 
   Protein Kinase A 
   Phosphodiesterase. 
   cGMP dependent protein kinase 
    Membrane bound guanylyl cyclase. 
    Hydrogen ion concentration. 
    Ortho phosphate. 
    Red blood c ells 
    Right side out vesicles. 
    Sodium dodycyl sulphate 
    Soluble guanylyl cyclase 
    Serial number. 
    Standerd deviation 





1.1. Cyclic nucleotides 
Cyclic nucleotides such as cAMP and cGMP are substances with a specific cyclic bond 
arrangement between the sugar and phosphate groups, and function as basic components in a 
communication system that acts within cells. They are important intracellular signal 




                             
     Cyclic adenosine monophosphate (cAMP) 
[30]
         Cyclic guanosine monophosphate (cGMP) 
[35]
       
                                           Figure 1: Structures of cAMP and cGMP. 
Inside the cell, second messengers transmit and amplify signals from receptors to downstream 
target molecules. They are rapidly synthesized and eliminated by cellular enzymes and by 
membrane transporters, rapidly sequestered in a membrane-bound organelle or vesicle or have 
a restricted distribution within the cell. 
[34]
 
The cellular biokinetics of cyclic nucleotides comprises three processes: synthesis, 
biotransformation and cellular extrusion. Precursors of cyclic nucleotides synthesis are ATP 





Figure 2: Cyclic nucleotides signaling pathway: NTP; nucleotide triphosphate, 5’NMP; 5’nucleotide mono phosphate, cNT; 
cyclic nucleotides, PDE; phosphodiesterase, ABCC; ABC- transporter. [9] 
Cyclic AMP is produced in cells through the activity of membrane bound adenyl cyclase. 
[15]
 
The majority of ACs are indirectly activated by various stimuli including adrenergic agonists, 
which bind to G protein coupled receptors (GPCRs) on the cell membrane resulting in the 
activation of the GPCR and release of the Gαs subunit that is subsequently responsible for 
binding to and activating AC, thus stimulating the production of cAMP.
[11, 17]
 Cyclic AMP is 
biotransformed into AMP by members of the phosphodiesterase enzyme family 
[31]
 and 
extruded unmodified to the extracellular space by ABCC transporters.  
                         
Figure 3: cAMP signaling pathway: ATP; Adenosine tri phosphate, 5’AMP; 5’ adenosine mono phosphate, GPCR; G protein 
coupled receptor, AC; adenyl cyclase, PKA: Protein kinase A, CAMP; cyclic adenosine mono phosphate, cGMP; cyclic 
guanosine mono phosphate PDE; phosphodiesterase, ABCC; ABC- transporter. [9] 
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Due to the activity of members from the guanylyl cyclases GTP is converted to cGMP. 
[34, 31, 
9]
  There are two different classes of guanylyl cyclases, the membrane bound form (PGC) and 
the soluble form (SGC). The PGC and SGC are stimulated by atrial natriuretic peptide (ANP) 
and nitric oxide (NO) respectively. Activity of phosphodiesterases decomposes cGMP in to 




Figure 4: cGMP signaling pathway: GTP; Guanosine tri phosphate, 5’GMP; 5’ guanosine mono phosphate, PKG; cGMP 
dependent protein kinase, PGC; membrane bound guanylyl cyclase ,SGC; soluble guanylyl cyclase, NO; Nitric oxide,  
cGMP; cyclic guanosine mono phosphate, PDE; phosphodiesterase, ABCC; ABC-transporter [9] 
While the specific function of a given signal varies according to 
a) The cell type 
b) Extracellular environment  
c) Stimulus activating the signal  
d) Localization of the signal and  
e) The type of cyclic nucleotide formed. 
Both the amplitude and duration of a cyclic nucleotide signal also vary and are largely 
dependent on the expression and activity levels of cyclic nucleotide phosphodiesterase (PDE) 
enzymes, which is responsible for hydrolyzing the cyclic nucleotide in order to terminate the 
signal. 
[9,18]
  It is commonly accepted that the total concentrations of cAMP and cGMP in 
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most cells are typically from below 1 µM up to 10 µM but the active free concentration being 
far lower. The transport of cyclic nucleotides out of the cells is energy requiring, dependent 
on ATP- hydrolysis. 
[29]
 
1.2. ATPases  
ATPases represent a large enzyme family by which some members can store chemical energy 
into high-energy phosphoanhydridic bonds in ATP and other members can utilize the stored 
energy for mechanical work such as transport of small inorganic or organic molecules against 
huge concentration gradients. An example of the first class is the F-type (Fo Fi type) or ATP 
synthase/H
+
 ATPase complex and examples of the second class is P-ATPases (transport 
ATPases) and m-ATPases (ABC-transporters).
 [19]
 The ability to stimulate ATPase is a 
hallmark of substrate translocation by ABC-transporters. The end products of the ATPase 
activity are ADP and an inorganic phosphate, orthophosphate (Pi). The enzyme activity can 
be determined by measuring the release of inorganic phosphate by colorimetry 
                        ATP     →       ADP   +   Pᵢ        
                                      ATPase activity     
1.3. ATP Binding Cassette (ABC) Transporters  
ABC-transporters belong to one of two principal transporter super-families, affecting cell 
membrane translocation of drug. ABC-transporters are primary active transporters requiring 
ATP hydrolysis. The mechanism includes the following steps, 
1. Opening of the channel toward the inside of the cell. 
2. Substrate binding and conformational changes in the ATP-binding cassettes. 
3. ATP binding and further conformational changes. 
4. Separation of the membrane-binding domains and release of the substrate to the other 
side of the membrane. 




                                               Figure 5:  ATP Binding Cassette Transporter mechanism 
[32] 
Members of subfamily C among the ABC-transporters play an important role in the extrusion 
of cyclic nucleotides. ABCC4 (MRP4) and ABCC5 (MRP5) are most important for the 
cellular extrusion of cGMP and cAMP. Previous studies of ATP-dependent transport support 
the idea that ABCC5 has high affinity for cGMP while ABCC4 has high affinity for cAMP.
 [3] 
ABCC5 contributes to cGMP export from human erythrocytes. At higher concentrations 
ABCC4 and ABCC5 can transport both cyclic nucleotides. 
[3]
 
1.4. Inside out vesicles from human erythrocytes. 
The different intracellular and extracellular behavior of biological membrane is result   of the 
membrane organization. To characterize individual surfaces, one possible technique is to seal 
the membrane in the form of vesicles.  These vesicles could be of the types, 
 Inside out vesicles (IOV): Cytoplasmic side of the membrane is outward. 
 Right side out vesicles (ROV): The external surface is still outward.  
For pharmacological studies of cyclic nucleotide extrusion, hRBC which possesses ABCC4 
[16, 20] 
and ABCC5 
[14, 16, 7, 4]
 are suitable choice. 
[33]
 These cells are easily and freshly 
obtainable and preparation of IOV makes it possible to characterize ATPase activity after 
stimulation with cGMP. 
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1.5. Aims of the work 
In the present work we have characterized an assay for determination of inorganic phosphate 
concentrations and employed this method to study basal and cGMP-stimulated ATPase 
activity in IOV from hRBC.  
 
The work aimed to  
1) Test the linearity of the inorganic phosphate standard curve.  
2) Determine the influence of membrane protein concentrations on the linearity of the 
inorganic phosphate assay (dilution studies). 
 3) The ability to distinguish basal ATPase activity from cGMP-stimulated activity in hRBC 
IOV and finally, 
 4) Compare the in-house method with a commercially ATPase available assay kit (Innova 














2. Material and methods 
 
2.1. List of chemicals 
An overview of chemicals used is given below. Detailed in formation of the chemical 
materials that were used to perform the experiments in the present work is shown in 
Appendix7.1. 
Substance (chemical formula) 
Sodium chloride (NaCl)    
Potassium chloride (KCl)                                                
Potassium hydroxide (KOH)                                            
EGTA ((CH2OCH2CH2N(CH2CO2H2)2)                                
HEPES (HOCH2CH2-N(-C2H2-)2N-CH2CH2SO3H)                
Magnesium chloride (MgCl2•6H2O)                                   
Pyrophosphate (Na4P2O7•10H2O)                                     
Phosphate basic (Na2HPO4•2H2O)                                   
Sodium hydroxide (base) NaOH                                      
Protease inhibitor cocktail                                                  
Cysteine (C3H7NO2S)                                                     
β-Nicotinamide adenine dinucleotide (NAD)                         
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB)                          
Histodenz                                                                             
Tris (HOCH2)3CNH2                                                                                               
Tris concentrated, acidic. (Tris•HCl)                                     
Potassium phosphate, acidic (KH2PO4)      
Potassium phosphate basic (K2HPO4•3H2O)                        
Sodium dodecyl sulphate    
Ouabain g-strophanthin (C29H44O12)                                  
Supplier 
Sigma-Aldrich  
Sigma-Aldrich                        
Merck                                                             
Sigma-Aldrich                         
Sigma-Aldrich                      
Merck     
Fluka  
Sigma-Aldrich                        
Merck                                 
Sigma                                       
Fluka                     
Sigma-Aldrich                            
Sigma- Aldrich                           
Sigma                                        
Merck                                      
Merck                                       
Merck                                        
Sigma                                        
 Sigma-Aldrich                             











P 8340    
30090 
N 3014  
D 21820 










2.2. Buffers and Solutions 
An overview of the buffer and solutions used is given below. Detailed information of the 
buffers and solutions is given in Appendix 7.2, 7.3 and 7.4. 
Buffer for cell washing 
HEPES buffer (HEPK): 10 mM, K
+
 8.6 mM , EGTA 2 mM,  NaCl 150 mM, pH = 7.50 
Phosphate Buffered Saline (PBS): Phosphate 10 mM, NaCl 137 mM, KCl 2.7 mM, pH = 7.40 
Buffers for cell lysis  
Lysis buffer # 1 (L1): EGTA 0.5 mM, MgCl2 2.0 mM, NA*2ATP 0.6 mM, HEPES 20 mM, K
+
 28.9 mM,  pH = 
7.50  
Lysis buffer # 2 (L2): EGTA 0.5 mM, HEPES 20 mM, K
+
 28.9 mM, pH = 7.50   
Buffers for IOV preparation  
Hypotonic lysis buffer A: Tris 5.0mM, K
+
 113 mM, Cl
- 
116mM, pH = 8.1 
Hypotonic washing buffer B: Tris 5.0mM, EGTA 0.5 mM, K
+
 4.0 mM, Cl
- 
5.6 mM, pH = 8,1 
Hypotonic vesiculation buffer C: Tris 0.5 mM, Cl
- 
0.2 mM, pH = 8.2  
Buffers for Sidedness 
Phosphate buffer with Triton X-100 (FX): Phosphate 5.0mM, Triton X-100 0.2%, pH = 8.0 
Ammonium molybdate (NH4)2MoO4                                                 
Ascorbic acid (C6H8O6)                                                                         
Hydrochloric acid ( HCl 37 % )                                           
ATP (Na2ATP)  
Arsenate (Na2HAsO4•7H2O)                                                
Acetylthiocholine-chloride (ATCCs)                                      
Triton X-100                                                                        
Cyclic guanosine monophosphate (cGMP)                              
Sigma                                   
Sigma-Aldrich                         
Sigma                              
Sigma                             
Fluka 
Sigma                                        
Sigma                             
Sigma    




71625                                   
A5626 




 Phosphate buffer with 0 detergent (F0): Phosphate 5.0mM, pH = 8.0 
Solutions for Sidedness test 
Incubation solution for sidedness 2 (IS2): DTNB (5, 5’ –dithiobis-(2-nitrobenzoic acid)) 0.7mM, phosphate 
100mM, pH = 7.5 
ATCC  olution: ATCC  Acetylthiocholine-chloride   water) 12.5mM.  tore at -70 C. 
IV0 (IOVs with 0 detergents): IOV + F0 
IVX (IOVs with Triton X-100). IOV + FX 
Solutions for ATPase assay for inside out vesicles: 
Incubation solution # 0 (IQ0) - for determination of basal (unstimulated) level: 
 Tris 51.7 mM, EGTA 5.18 mM, ATP 10.35 mM, Mg
2+
 10.35 mM, Ouabain 5.2 mM, K
+
 728.6 mM, Cl
-
 39.8 
mM.( See safety aspects note 1in appendix 7.4) 
Incubation solution # 1 (IQ1) - for determination of cGMP-stimulated level:  
Tris 50.0 mM,  EGTA 5.0 mM,  ATP 10.0 mM, Mg
2+
10.0 mM, Ouabain 5.0 mM, K
+
 704.3 mM, Cl
-
 715.1 mM, 
cGMP 50 µM (microMolar) 
 Incubation solution # 2 (IQ2) - for determination of without cGMP-stimulated level: 
Tris 50.0 mM, EGTA 5.0 mM, ATP 10.0 mM, Mg
2+
10.0 mM, Ouabain 5.0 mM, K
+
 704.3 mM, Cl
-
 715.1 mM, 
cGMP 0.0 µM (microMolar)  
Final Incubate # 1 (FIQ1) - for determination of ATPase activity of IOVs with cGMP stimulation:  
Tris 10.0 mM,  EGTA 1.0 mM,  ATP 2.0 mM, Mg
2+ 
2.0 mM, Ouabain 1.0 mM, K
+
 140.9 mM, Cl
-
 143.0 mM, 
cGMP 10 µM (microMolar), pH = 8 
Final Incubate # 2 (FIQ2) - for determination of ATPase activity of IOVs without cGMP stimulation: 
Tris 10.0 mM,  EGTA 1.0 mM,  ATP 2.0 mM, Mg
2+ 
2.0 mM, Ouabain 1.0 mM, K
+
 140.9 mM, Cl
-
 143.0 mM, 
cGMP 0.0 µM (microMolar), pH = 8 
Reaction Inhibitor (SDS): Sodium dodecyl sulphate 12% 
Coloring Reagent (BC): Ascorbate 3%, HCl 700mM, Ammonium molybdate 0.5 %.( See safety aspects note 2, 3 







2.3. List of Individual procedures 
 
1. Preparation of IOV from human erythrocytes (Red blood cells, or RBC). 
2.  Phosphate assay and different phosphate concentrations. 
3. Phosphate assay and the effect of different concentrations of cGMP 
4.  ATPase assay for IOV. 
a. Phosphate assay of IOV in presence and absence of cGMP. 
b. Effect of different IOV concentrations on ATPase assay.  
c. Difference in absorbance in presence and absence of IOV. 
d. ATPase assay with higher IOV concentrations. 
e. ATPase assay with higher IOV concentrations with modified protocol.   
f. ATPase assay of IOV with commercial kit. 
2.4. Preparation of IOV from human erythrocytes (hRBC) 
 
Mature human erythrocytes have a maximal diameter of about 7.4 µm. Due to their extreme 
flexibility they can deform and pass through capillaries with a size of 1.5 µm. There are at 
least two reasons for this flexibility. First, during maturation the nucleus is expelled and the 
cells go into a final life span of 120 days in average. Secondly, the cell membrane has a 
specialized composition that favors flexibility. This is also the reason why the membrane of 
these cells under certain conditions invaginates to form IOV or protrude to form ROV.  
In the present study, IOV were prepared with a modification of the method originally 
described by Steck. 
[24]
 Figure 6 shows the principle steps of the method. Fresh human EDTA 
blood was collected and all steps were performed at 0°C - 4°C. The cells were sedimented by 
centrifugation. RBC were washed three times with buffer A (pH 8.1) for hypotonic lysis. The 
cells were resedimented and lysed in 10 volumes of buffer B (pH 8.1), then rewashed in the 
same buffer B until ghosts were milky white. To initiate hypotonic vesiculation 49 volumes of 
cation free buffer C (pH 8.2) were suspended to one volume of cell suspension.    The volume 
suspension is resedimented and homogenized by passing through a 27G cannula. A density 
gradient was used to separate IOV, ROV and ghosts by overnight ultracentrifugation. The 
uppermost band was collected, washed and resuspended in buffer C. A detailed procedure is 






                 
                     Figure 6:  Diagramic illustrations of preparation of IOVs form hRBC (ill.: Roy Lysaa). 
 
A: Enlarged view of normal human erythrocytes membrane. B: Human erythrocyte. C: Hypotonic lysis for the removal of 
cell contents. D: Erythrocytes ghosts after hypotonic washing. E: Hypotonic vesiculation after incubation with very low ionic 
strength alkaline buffer. F: Shear applied for homogenized sealed IOV. G: Enlarged view of an IOV and ROV. 
2.5. Sidedness of vesicles 
Using acetylcholinesterase accessibility sidedness of the ghosts was verified with small 
modifications to the original method. 
[8] 
 
The enzyme acetylcholinesterase (AChE) is anchored to the cell membrane and is located at 
the extracellular side of the membrane. For the inside out vesicles the situation is the opposite. 
IOV should give low AChE-activity, while ROV should give high AChE-activity. By 
measuring the activity of this enzyme at the extravesicular side, the relative fractions of IOV 
and ROV can be found. The existence of AChE-activity in IOV is controlled by using the 
detergent Triton-X100 that makes the membrane leaky. In the presence of this detergent, any 
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extravesicular substrate will also become available for intravesicular enzyme; then both IOV 
and ROV will give high AChE-activity.  
2.6. Phosphate assay and different phosphate concentrations 
In 1925 Fiske and Subbarow first described the method of colorimetric determination of 
inorganic phosphate with ammonium molybdate complexes.
[10]
 Since then, many 




Different concentrations of phosphates (5 µM, 15 µM, 25 µM, 50 µM, 100 µM and 250 µM) 
were prepared. Addition of coloring reagent made a color complex with free phosphates. 
Absorbance of analytes measured was directly proportional to the amount of available 
inorganic phosphates. 
2.7. In-house phosphate assay 
The ATPase activity is determined by measuring the release of inorganic phosphate generated 
from ATP hydrolysis by colorimetry. 
 To measure ATPase activity analytes are incubated in a solution or reaction medium with pH 
8.0 that optimizes transport activity for the assay. The solution is incu ated at 37  C for 
suggested time and then reaction was stopped by using SDS 12%. Addition of coloring 
reagent is making a color complex with free phosphates. Absorbance of analyte is directly 
proportional to the amount of available inorganic phosphates  
The ATPase activity of the ABC-transporter in hRBC IOV was determined by colorimetric 




While describing, “A method for the determination of inorganic phosphate in the presence of 
labile organic phosphate and high concentrations of protein” he used sodium dodycyl sulfate 
(SDS) to stop the enzymatic reaction resulting not to develop color immediately while 
working with large number of samples since there is no further organic phosphate hydrolysis. 
For color development, he used a freshly prepared solution of 6% ascorbic acid in 1 N HCl 





For current study to characterize ATPase activity in IOV of human erythrocytes after 
stimulation with cGMP, we used a modified version of method adopted from Chifflet and 
Boadu & Sager.  
[6] [3]
 
Inside out vesicles of human erythrocytes were stored at -70 C in microcentrifuge tubes. 
Required numbers of tubes was taken out of freezer and were kept in ice box at    C. The 
thawn IOV were added in the presence of cGMP in a solution with pH  .0 at 37  C that 
optimizes transport activity are incubated for suggested time. The transport reaction starts 
when IOV are mixed in. Reaction was stopped by using SDS 12%. Addition of coloring 
reagent made a color complex with free phosphates. Absorbance of analytes measured was 
directly proportional to the amount of available inorganic phosphates. 
2.8. Commercial phosphate assay 
Since 1925, different types of procedure have been used for the colorimetric determination of 
inorganic phosphate. Basic principle behind is, the formation of a colored complex of 
available Pi and coloring reagent used. Colorimetric detection of the color complex of 
ammonium molybdate and free Pi was a widely used technique for inorganic phosphates. 
In 1965 Itaya and Koich, tested other dyes including safranin, brilliant green, malachite green, 
fuchsin red, methylene blue, methyl violet while working for “New micro method for the 
colorimetric determination of inorganic phosphate”. They observed by adding 1 µg per ml of 
inorganic phosphate into the acidified solution of basic dyes containing ammonium molybdate 
resulted that malachite green not only produced the high intensity of color but also with a 
marked shift to the absorption maximum by exposure to phosphomolybdate, showed most 
significant behavior as the color developing reagent for micro-determination of phosphate.
 [13]
 
Commercial ATPase assay kit by Innova Biosciences: 
The ATPase colorimetric assay kit by Innova Biosciences employs all reagents necessary for 
measuring ATPase activity. The kit contains PᵢColorLock™ Gold reagent  an improved 
malachite green formulation) with additives to prevent background signals arising out of non-
enzymatic ATP hydrolysis. Assay can be read anywhere in the wavelength range 590- 660nm. 
Principle of the ATPase assay kit: 
                                   ATP → ADP       Pᵢ       Dye 
                                             ATPase                 └──────┘ 
                                                                                Pᵢ -dye 
                                                                              Complex 




In order to measure “Cyclic nucleotide dependent ATPase activity in inside out vesicles from 
human erythrocytes”, a series of experiments were performed following the protocols. The 
raw data obtained is mentioned in Appendix 7.6. Final results, obtained are described in this 
chapter. 
Firstly, inside out vesicles from human erythrocytes were prepared and tested for sidedness. 
 
 3.1. Sidedness test of IOV: 
Three different batches of IOV were prepared and tested for sidedness, following yields were 
obtained. 
Table 1: The table is about sidedness of vesicles and shows mean % yield for IOV and ROV 
obtained from three experiments. 
 
  
   Batch 1 
 
      Batch 2 
 
    Batch 3 
%  IOV      50          26          28 
%  ROV      50           74         72 
 
        
Total obtained volume of vesicles were distributed in 1mL aliquots, labeled them with 
percentage, date of preparation and stored at -70  C to reuse them as per required. 
For performing the next series of experiments to measure, cyclic nucleotide dependent 
ATPase activity in inside out vesicles from human erythrocytes , the batch (batch 1) of 






3.2. Phosphate assay and different phosphate concentrations 
Table 2: The table shows absorbance (at 680 nm) of different concentrations of phosphates in µM 
with and without cGMP. To measure absorbance for each phosphate concentration e.g. (5 µM) three 
parallels with cGMP and three parallels for same phosphate concentration but without cGMP were 
prepared to avoid possible errors. Absorbance measured at wavelength 680 nm for each parallel is 
represented by a, b, and c, also calculated the mean and standard deviation for both (phosphate 
concentration with and without cGMP).   
Phosphate 
Conc.                                          Absorbance  x  100      
      
 
with cGMP 
     
without cGMP 
   
       µM A  b c Mean   SD 
 
a b C Mean SD 
  
 
   
 
       5 0,9  0,3 0,6 0,6  0,14 
 
0,2 0,5 0,4 0,4 0,12 
 
15 1,2  1,3 1,1 1,2  0,08 
 
1,3 0,7 0,6 0,9 0,31 
 
25 4,9  4,8 4,8 4,8  0,02 
 
4,6 4,5 4,3 4,5 0,12 
 
50 10  9,3 9,8 9,7  0,22 
 
9,7 8,9 7,5 8,7 0,91 
100  
 
   
 
       21,7  ------ 25,8 23,8  1,03 
 
20,4 20 20,8 20,4 0,33 
250 30,3  33,3 28,0 
 




27,7 28,3 0,45 
 
             Figure 7: The figure shows mean values from table 2.  
 
 
Table 2 and figure 7 shows that the phosphate concentrations appear to be higher in the 
presence of cGMP, probably due to degradation of cGMP with liberation of phosphate. The 






















3.3. Phosphate assay and the effect of different concentrations of cGMP 
Table 3: The table shows absorbance (at 680 nm) for different concentrations of cGMP and 
phosphate in the same concentrations to measure the color absorbance. For each concentration three 
parallels for cGMP and three parallels for same phosphate concentration were prepared. Absorbance 
measured at wavelength 680 nm for each parallel is represented by a, b, and c also calculated the mean 
and standard deviation for both (dilutions of phosphate concentration and dilutions of cGMP).   
Dilutions 
Conc.µM 
          Absorbance X 1000 
                   With cGMP With phosphate dilutions 
a  b c Mean   SD 
 
a b C Mean SD 
  
 
   
 
       0.5µM -7,0  -6,0 -9,0 -7,3  1,2 
 
5,0 2,0 1,0 4,0 1,7 
 
5 µM -8,0  -9,0 -9,0 -10  2 
 
3,0 2,0 3,0 3,0 0,5 
 
25 µM -8,0  -6,0 -9,0 -9,0  1,2 
 
9,0 9,0 10,0 9,3 0,5 
 
50 µM -13,0  -7,0 -7,0 -9,0  0,9 
 
21,0 21,0 22,0 21,3 0,5 
100 µM  
 
   
 
       -9,0  -8,0 -8,0 -8,3  0,2 
 
46,0 39,0 40,0 42,0 3,1 
 
Figure 8: The figure shows the effect of cGMP and inorganic phosphate in identical concentrations 




Figure 8 shows that the solutions of cGMP do not increase absorbance when present alone in 



















Different Dilutions Concentrations 
cGMP solutions 
phosphate  solutions 
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3.4. Phosphate assay of IOV in presence and absence of cGMP 
Table 4:  
This table shows the absorbance obtained at 680 nm for IOV in absence and presence of 10 
µM cGMP incubated for 60 min at 37°. Reaction was stopped by using SDS 12%. Addition of 
coloring reagent made a color complex with free phosphates. Absorbance of analytes 




Table 4 shows that 13 of 17 tests had higher phosphate level in presence of cGMP, compatible 
with a cGMP-stimulated ATPase, whereas two were higher without cGMP addition and two 




Sr.# Absorbance at 680nm x 100 
  Without cGMP          With cGMP 
1 7,6 7,7 
2 8,1 7,8 
3 7,6 8,1 
4 8,0 8,3 
5 
8,0 8,1 
6 7,9 8,1 
7 7,5 8,0 
8 
7,8 8,0 
9 8,0 8,0 
10 8,2 8,5 
11 
8,4 8,6 
12 8,1 8,7 
13 8,6 8,5 
14 
8,5 8,5 
15 8,5 8,9 





3.5. Effect of different IOV concentrations on ATPase assay: 
A linear increase in absorbance would be expected with increasing IOV concentrations. IOV 
in absence and presence of cGMP were tested three times, following same protocol.  
Table 5: The table shows difference of absorbance (at 680 nm) in percent for different concentrations 
of IOV from three different experiments, represented as Exp1, Exp 2 and Exp 3. 
 
IOV conc. 
   % 
         
          Difference of absorbance at 680nm (%)  
     (abs. with cGMP – abs. without cGMP) / Max Abs.)  x 100 
 
 
         
 
             Exp 1 (%) 
 
               Exp 2 (%) 
 
               Exp 3 (%) 
        
       25 58,8 6,5 9,7 
 
       50 60,8 8,7 11,7 
 
        75 65,7 -18,1 13,6 
        
       100 66,7 13,0 14,6 
 
Figure 9: The figure shows three independent experiments with cGMP-stimulated ATPase activity as 
function of IOV concentration. The three curves represent Exp1 (Z1), Exp2 (Z2) and Exp3 (Z3).  
 
With the exception of the third point in experiment Z2 all experimental points indicate an IOV 
concentration-dependent increase in phosphate production. However, the specific activity 
























































3.6. Difference in absorbance in presence and absence of IOV 
 
These experiments were performed to measure the background absorbance (reagent blank) 
and determine whether IOV gave additional increase in absorbance.  
 
Table 6: The table shows the optical absorbance x100 obtained at 680nm at 40 minutes for two 
different samples with and without IOV in the absence of cGMP. The samples were incubated for 60 





  Absorbance x 100 
 
  With IOV   Without IOV 
 
      13.0 
 
    10.0 
       
      13.0 
 
    9.0 
       
      13.1 
 
    9.0 
 
Mean Absorbance  
 
      13.0 
 
    9.3 
 
 
The experiments were conducted to demonstrate that the reaction mixture with IOV gave 
higher phosphate levels than without. Table 6 shows a small but distinctive increased 
absorbance when IOV were present. This represents basal ATPase activity. The absorbance 









3.7. ATPase assay with higher IOV concentrations 
 
These experiments were performed to see whether higher concentrations of vesicles gave 
higher specific activity (the difference in absorbance with cGMP and without cGMP). The 
IOV-stock used here were less diluted than before, i.e. 6 times more concentrated  
 
Table7: The table shows the difference of absorbance (at 680 nm at 40 min) in percent for different 




   % 
         
          Difference of absorbance at 680nm In percent 
                (abs. with cGMP – abs. without cGMP) / Max Abs.)  x 100 
                                                    
 
        X 
 
              Exp 1 (%) 
 
              Exp 2(%) 
 
                Exp 3 (%) 
        
       25 5,3 80,9 1,7 
  
       50 1,1 66,0 13,6 
 
        75 29,8 76,6 6,8 
        
       100 42.6 63,8 8,5 
 
 
The results of these experiments (table 7) are not consistent and the expected linear increase 









3.8. ATPase assay with higher IOV concentrations with modified protocol 
Based on the unsatisfactory results in section 3.7 (table 7) the protocol was modified ( see 
Appendix 7.5.8 ) and for these experiments not only 6 times concentrated IOV- stock was 
used but also decided to remove maximum possible phospholipids before adding color 
reagent so that absorbance recorded should be of only inorganic phosphate released during 
ATPase.  
Table 8: The table shows the difference of absorbance, the specific cGMP stimulated activity (with 
10 µM cGMP for 60 min incubation at 37°C) in percent for different concentrations of IOV from three 




   % 
         
          Difference of absorbance at 680 nm (%) 
                (abs. with cGMP – abs. without cGMP) / Max Abs.)  x 100 
 
 
        X 
 
              Z1 (%) 
 
               Z2 (%) 
 
            Z3 (%) 
        
       25 58,8 7,5 9,9 
 
       50 60,8 10,0 13,9 
 
        75 65,7 19,2 14,9 
        
       100 66,7 20,8 15,8 
 
Figure 10: The figure shows IOV concentration along X-axis and difference of absorbance in percent 
(Z) along Y-axis. Three curves representing Z1, Z2 and Z3  for  Exp 1, Exp 2, and Exp 3 respectively, 






















































After modification of the protocol the expected results occurred. The cGMP-stimulated 
ATPase activity increased as a function of IOV concentration.  However, Exp1 showed 
clearly higher specific activity than Exp 2 and Exp 3, which were grouped together.  In a more 
detailed analysis of the single experiments it was shown that trend lines for  Exp1, Exp2 and 
Exp3  were described by y = 0,1137x + 55,88 (R² = 0,9397), y = 0,1966x + 2,085 (R² = 
0,9222) and y =0,0752x + 8,91 (R² = 0,8699), respectively. This data suggests that linearity 
exists. 
 
3.9. ATPase assay of IOV with commercial kit 
The following experiments were undertaken to obtain experience with a commercial ATPase 
kit (Innova Biosciences).  
Table 9:  
The table shows difference of absorbance (at 635 nm) in percent for different concentrations of IOV 





   % 
 
           Difference of absorbance at 635 nm In percent 
                 (abs. with cGMP – abs. without cGMP) / Max Abs.)  x 100  
 
 
        
 
             Exp 1 (%) 
 
             Exp 2 (%) 
 
                  Exp 3 (%) 
        
       25 44,6 0,7 6,5 
 
       50 45,2 0,9 6,7 
 
        75 52,3 3,3 6,8 
        
       100 69,0 8,3 7,7 
 
Figure 11:  
The figure shows the difference of absorbance in percent along Y-axis as a function of IOV 
concentration. Three curves representing Z1, Z2 and Z3 for Exp 1, Exp 2, Exp 3, are showing linear 






The commercial kit gave results that showed a trend of relation between phosphate 
concentration and % IOV, The cGMP-stimulated ATPase activity increased as a function of 
IOV concentration.  However, Exp 1 showed clearly higher specific activity than Exp 2 and 
Exp 3, which were grouped together.  In a more detailed analysis of the single experiments it 
was shown that trend lines for  Exp 1, Exp 2 and Exp 3 were described by y = 0,3218x + 
32,655 (R² = 0,8312), y = 0,101x - 3,015 (R² = 0,846) and  y = 0,0166x + 5,91 (R² = 0,9153), 































































The current study was conducted to characterize cyclic nucleotide dependent ATPase activity 
in inside out vesicles from human erythrocytes. As described earlier, one class of ATPases 
utilizes stored energy (ATP) to produce useful work against concentration gradients e.g. m-
ATPase or ABC-transporters.
 [33] 
These are primary active transporters which require ATP 
hydrolysis for translocation of substance across cell membrane. 
In recent years much work has been done regarding ABC (ATP-Binding-Cassette) 
transporters. In almost all living cells the members of this transporter family have been 
identified. 
[33, 5]
 Pharmacological studies of cyclic nucleotide extrusion confirmed, human 
erythrocytes (hRBC) which possess ABCC4 
[16, 20] 
and ABCC5 
[14, 16, 7, 4]
 a suitable choice. 
[23]
 
We believe that ABCC4 is a selective high affinity transporter for cAMP whereas ABCC5 is 
selective high affinity transporter for cGMP
 [23]
 but that both proteins transport both 
nucleotides with low affinity.
 [33]
 Previous studies support the concept that cGMP transporter 
also requires lipid environment for ATPase activity like other membrane bound protein 
ATPases. 
[4] 
There are biochemical evidences available explaining the functions of cGMP efflux pump, 
showing transport is dependent on ATP 
[21] 
and ATP hydrolysis 
[23]
 with magnesium as 
activator. 
[26, 27, 5] 
 
                                   Figure 12:  ABCC5 Transporter and ATPase activity (ill.: Roy Lysaa). 
 
A: Inward opening of the transporter domain. B: Substrate binding causing conformational change. C: ATP  inding → 
separation of the membrane- inding domains →  u strate release to the outward → ATP hydrolysis. D: Transporter is 
resettled to its initial. 
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In present study we have characterized an assay for determination of inorganic phosphate 
concentrations and employed this method to study basal and cGMP- stimulated ATPase 
activity in IOV from hRBC. 
 The project was divided in three parts 
1. Preparation of IOV from hRBC. 
2. Characterization of ATPase activity in IOV of hRBC after stimulation with cGMP, 
aimed to design in-house assay method for. 
 Test of linearity of inorganic phosphate standard curve. 
 Determine the influence of membrane protein concentrations on the linearity of 
the inorganic phosphate assay (dilution studies). 
 The ability to distinguish basal ATPase activity from cGMP-stimulated 
activity in hRBC IOV and finally, 
3.  Compare the In-house assay with commercially available kit (Innova Biosciences) to 
make cost beneficial analysis. 
  
4.1.     Preparation of IOV from hRBC and sidedness test: 
 
The first part of the project was to prepare IOV from hRBC.  
As known from previous studies biological membrane have differential two compartment 
behavior because of the different molecular constituents of both surfaces.  The principal 
feature of membrane organization is this asymmetry. 
To characterize the individual surfaces behavior suggestion was to prepare membranes, sealed 
into vesicles of one specific orientation by following step by step approach. 
[25]
  
So for present study three different batches of inside out vesicles (IOV) were prepared from 
freshly drawn human blood and tested for sidedness.  
As mentioned in chapter RESULTS (3.1) three different percentage yields of IOV were 
obtained.  
The percentage yield of IOV is presented below:  
o From batch 1 was 50% 
o From batch 2 was 26% 
o From batch 3 was 28%. 
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yield was almost half of the 1
st
 value. This varying percentage yield of IOV may have 
different explanations. 
 Incubation time in IOV permeable buffer varied, in first batch it was exactly 
according to protocol only 2 hours. But in other cases due to the length of experiment, 
ghosts left incubated overnight. 
 Another possible reason could be any possible contamination causing change in pH 
resulting IOV permeability behavior of incubating buffer. 
 There was also possibility of movement even minor shaking could result in disturbing 
of two phase layers while doing phase separation after treating with density gradient. 
Following proposals are recommended for future investigations. 
 Incubating time and temperature should be constant and according to the protocol. 
 Handle two phase density gradient layers gently but with high stability while 
separating two phases. 
 Recommended to use freshly prepared incubating buffer to avoid pH variation. 
 
4.2. Characterization of cGMP stimulated ATPase activity in IOV of 
hRBC  
The second step of the project was to characterize ATPase activity in IOV of hRBC after 
stimulation with cGMP.  
The idea was to design an in-house assay method for the determination of inorganic 
phosphate concentrations and to employ this method for basal and cGMP stimulated ATPase 
activity in IOV from hRBC.  
It was in 1925 Fiske and Subbarow used colorimetric technique for determination of 
phosphomolybdate complexes since then many modifications have been made and now it is 
widely used biochemical technique. 
 [1, 2, 10, and 13]
 
Further investigations confirmed that the ATPase activity is determined by measuring the 
release of inorganic phosphate generated from ATP hydrolysis by colorimetry. ATPase 
activity for IOVof human erythrocytes is a function of substrate binding and leads to substrate 
translocation by the ABC-transporter. In current studies a modified assay method based on the 
work of Chifflet and Boadu & Sager 
[6, 3]    
was designed using principle elements,  
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a) Transporter: Human erythrocytes contain ABCC5 transporters which are suitable for 
measuring cGMP derived ATP hydrolysis.  
b) Substrate: Transported substrate regulates the ATPase activities of several 
transporters, for stimulating the ATPase activity of the cGMP transporter, cGMP was 
used. 
[3]
 To avoid competing low-affinity transporters, it is recommended to use not 
more than 10 µM concentration of cGMP. 
c) Inhibitors: Since there is a number of other ATPases in the cell, these have to be 
blocked by specific inhibitors. 
 Na+/   K+-ATPase is inhibited by 1 mM Ouabain. 
 Ca2+-ATPase is inhibited by 2 mM EGTA. 
This part of the project was aimed to,  
1. Test the linearity of the inorganic phosphate standard curve.  
2. Determine the influence of membrane protein concentrations on the linearity of the 
inorganic phosphate assay (dilution studies).  
3. The ability to distinguish cGMP-stimulated activity from basal ATPase activity in 
hRBC IOV.  
 
4.2.1. Test the linearity of the inorganic phosphate standard curve 
 In biological systems phosphate is widely available, multifunctional inorganic ion which 
plays important role in regulating protein kinase and phosphatases dependent enzyme activity. 
Previous studies suggest that there is significant linear relation between amount of phosphate 
released and absorbance measured. To test this linear behavior, initially a phosphate assay 
was conducted using six different phosphate concentrations (5 µM, 15 µM, 25 µM, 50 µM, 
100 µM, and 250 µM) which were incubated at 37 ºC in solution with and without cGMP to 
optimize activity and colorimetric analysis resulted that in the presence of cGMP phosphate 
concentrations tend to have higher absorbance probably due to cGMP degradation as shown 
in table 2 figure 7. This difference was much prominent with 25 µM and higher phosphate 
concentration and appeared to be virtually linear between 0 and 100 µM, so it was decided to 
ignore phosphate concentrations less than 25 µM in next series of experiments. Phosphate 
concentration of sample can also be determined by formula  
               Phosphate Concentration = (sample abs. – blank abs.) 
                                                            (slope of standard curve) x (μl of sample) 
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During an ATPase activity to justify the role of cGMP and inorganic phosphate in color 
complex formation, a phosphate assay for different concentrations of cGMP, and phosphate 
solutions of same concentrations was performed. Amount of cGMP is replaced with water in 
incubation solution. Dilution series (0.5 µM, 5 µM, 25 µM, 55 µM, 100 µM) for same 
concentrations of phosphate solution and cGMP solutions are prepared and analysed 
following the protocol. The results of this experiment presented in table 3 and figure 8 
showed, during phosphate assay, cGMP has no role in color development. Color development 
is due to phosphate released during incubation time. So testing the linearity of the inorganic 
phosphate standard curve concluded that the phosphate assay is linear but influenced by the 
presence of cGMP and color development is a function of phosphates released during the 
assay. 
As described earlier colorimetric determination of inorganic phosphate as a result of ATP 
hydrolysis is a function of ATPase activity in any biological system. This assay method was 
decided to use for further more ATPase analysis of IOV from human erythrocytes.  
 
4.2.2.  Influence of membrane protein concentrations (dilution studies) 
 
In Pharmacological studies of biological membrane proteins,  for assaying substrate transport 
in primary transport systems, IOV are first choice as supply of ATP to the transport system is 
exofacial in IOV, which provide the driving force for substrate transport. 
[28]
.  
To figure out the influence of membrane proteins concentrations it is expected that with 
increasing IOV concentrations there would be a linear increase in absorbance measured. 
Keeping this in mind to test the effect of different IOV concentrations an ATPase assay for 
IOV was performed, using phosphate assay method where concentrations of phosphate are 
replaced with concentrations of IOV with vesicles dilution of 25 %, 50 %, 75 %, 100 % and 
incubated at 37 ºC in the solution with and without cGMP to optimize activity. For each IOV 
concentration e.g. 25 % three parallels with cGMP and three without cGMP were prepared to 
avoid possible errors also measured the optical absorbance (OD) at 40 minutes and 
wavelength 680 nm. For the precise results this experiment following the same protocol was 
performed three times. For each experiment protein concentration of vesicles was different as 
for each experiment 1ml aliquot of pre frozen IOV suspension was thawed and used for 
making dilutions so for analyzing the data obtained, the difference of absorbance in percent 
was calculated and plotted against IOV concentrations in  table 5 and figure 9. The curves 
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obtained from experiment 1 and 3 showed an increasing linear behavior in terms of increasing 
IOV concentrations where as experiment 2 does not fully supports the concept rather showing 
negative value at 75 % IOV concentration. The explanation for this is not clear and with the 
exception of this particular point all experimental points indicates an IOV concentration –
dependent increase in phosphate production. 
During behavior studies of influence of membrane protein concentrations, the effect of higher 
IOV concentrations was a question of interest apparently suggested that higher concentrations 
of inside out vesicles will give higher specific activity so that new experiments were 
performed by six times concentrating the IOV using centrifugation technique and this 
concentrated IOV stock suspension was used to make (25 %, 50 %, 75 % and 100 %) dilution 
series. Rest of the procedure was unchanged. Final data obtained is shown in table 7. The 
results of these experiments are not consistent and expected linear increase in absorbance as a 
function of IOV concentrations is absent. This finding suggested that might IOV are also 
playing some role in color development activity and may be possible cause of this strange 
non-linear pattern. Although lipid environment supports the ATPase activity but to verify the 
catalytic role of phospholipids presents in IOV and to limit their activity in color 
development, is a function of determination of free inorganic phosphate released during 
ATPase. So based on unsatisfactory results from above mentioned experiment the protocol 
was modified and the suggestions were; use of concentrated IOV stock suspension, removal 
of maximum possible phospholipids before adding color reagent and increasing the color 
reaction time.  Next experiments with slight modifications in protocol were performed. The 
modifications made in protocol are as below, 
 Used six times concentrated IOV stock suspension involving centrifugation technique 
to make further vesicle dilution of 25 %, 50 %, 75 %, and 100 % for confirming 
maximum amount of IOV per dilution concentration. 
 After incubation times is over, all the samples with or without cGMP were centrifuged 
at 13000 RPM for 15 min to get rid most of the phospholipids. 
 In last, optical absorbance (OD) measured at 680 nm wavelength and at 60 minutes 
believing that increased reaction time for color development might give more 
significant absorbance value.  
After modification of the protocol expected results occurred as shown is in table 8 and figure 
10. All three curves for experiment 1, 2 and 3 are showing increase cGMP stimulated ATPase 
activity. In more detailed analysis of the single experiment it was shown that trend lines for  
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Exp 1, Exp 2 and Exp 3  were described by y = 0,1137x + 55,88 (R² = 0,9397), y = 0,1966x + 
2,085 (R² = 0,9222) and y =0,0752x + 8,91 (R² = 0,8699), respectively. This data suggested 
that linearity exists and concluded that Increasing dilution series of IOV, stimulated with 
cGMP have relative increasing ATPase-activity. The amount of IOV present in a particular 
concentration is directly proportional to absorbance, and plasma membrane lipids 
(phospholipids) present in IOV of human RBC are responsible for modulation of the catalytic 
activity of cGMP dependent ATPase. 
4.2.3. The ability to distinguish cGMP stimulated ATPase from basal ATPase 
 
To confirm the behavior of hRBC inside out vesicles in term of the ability to distinguish 
cGMP stimulated activity from basal ATPase activity following experiment was conducted. 
For measuring cGMP stimulated ATPase activity of IOV, phosphate assay of IOV in presence 
and absence of cGMP was performed where phosphate different concentrations were replaced 
with same concentration of IOV.  Seventeen parallels were prepared and OD at 40 minutes 
was measured to get relative clear picture results obtained are presented in table 4 shows that 
13 of 17 tests had higher phosphate level in presence of cGMP, compatible with a cGMP-
stimulated ATPase, whereas two (sample 2 and 13) were higher without cGMP addition and 
two were not different. Overall IOV in the presence of cGMP have increase ATPase activity. 
While talking about basal ATPase activity of IOV, without cGMP stimulation, the difference 
in absorbance in presence and absence of IOV is an important consideration. An experiment 
was performed to measure absorbance of reagent blank (without IOV) and comparing with 
absorbance of IOV to determine whether IOV gave additional increase in absorbance in the 
absence of cGMP stimulus. Two analytes were prepared with and without IOV in the absence 
of cGMP following the assay procedure, optical absorbance at 680 nm was measured. 
Observations were shown in Table 6 resulted, the reaction mixture with IOV gave higher 
phosphate levels than without, by a small but distinctive increased absorbance without cGMP. 
The findings supported the concept that hRBC IOV shows basal ATPase activity in the 
absence of cGMP which is might due to phospholipids presents in IOV and may be these 
phospholipids are playing role in color development. Removal of most phospholipids after 
stimulation with cGMP incubation would possibly decrease external phosphates available for 
color complex formation during ATPase assay. Finally concluding that IOV of human 
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erythrocytes posses basal ATPase activity in the absence of cGMP where as cGMP stimulated 
IOV of hRBC have comparative higher ATPase activity. 
At this point we concluded to perform further experiment for the 2
nd
 part of the project “to 
characterize ATPase activity after stimulation with cGMP”. Experimental work  done for this 
study lead us to design an assay method which can be utilize as an in-house  ATPase assay 
and is a modified version of method based on the work of Chifflet and Boadu & Sager.
 [6, 3]
 
Summarizing the second part of the project, key points are,  
 The phosphate assay is linear but influenced by the presence of cGMP. 
 Color development is a function of phosphates released during assay activity. 
 Increasing dilution series of IOV, stimulated with cGMP have relative increasing 
ATPase activity. 
 The amount of IOV present in a particular concentration is directly proportional to 
absorbance. 
 IOV of human erythrocytes have basal ATPase activity in the absence of cGMP where 
as cGMP stimulated IOV of hRBC have comparative higher ATPase activity. 
 Plasma membrane lipids (phospholipids) present in inside out vesicles of human RBC 
are responsible for modulation of the catalytic activity of the cGMP dependent 
ATPase. 
4.2.4. ATPase Assay by commercially available kit: 
An experiment was set for measuring ATPase activity in IOV of human erythrocytes by 
ATPase commercially available kit. For this study ATPase Assay kit by Innova Biosciences 
was recommended. The kit is provided with PᵢColorLock™ Gold reagent  an improved 
malachite green formulation) with additives to prevent background signals arising out of non-
enzymatic ATP hydrolysis.  According to the instructions by supplier and following the 
procedure protocol, assay was performed and optical density at 635 nm and was recorded.  
After data analysis final observations are shown in table 9 and figure 11, a trend of relation 
between phosphate concentrations and % IOV, the cGMP-stimulated ATPase activity 
increased as a function of IOV concentration.  However, In a more detailed analysis of the 
single experiments it was shown that trend lines for  Exp1, Exp 2 and Exp 3 were described 
by y = 0,3218x + 32,655 (R² = 0,8312), y = 0,101x - 3,015 (R² = 0,846) and  y = 0,0166x + 





in case of in-house ATPase assay method were more close to 1 than that of Innova 
Biosciences ATPase assay kit. 
4.3. Comparing In-house assay  with commercial ATPase assay kit: 
As mentioned before in aims of work last part of the current study was to compare, in-house 
assay method with commercially available ATPase assay kit to make cost benefit analysis. 
For this purpose above mentioned ATPase Assay kit from Innova Biosciences was used and 
compared under following parameters. 
a. Authenticity / Reliability of method 
b. Precision  and accuracy of results 
c. Time to get result 
d. Cost.   
e. Others (if there, mention it). 
Findings, after comparing both methods for above mentioned parameters are discussed in 
briefs as below. 
Authenticity / Reliability of method: 
While talking about authenticity of methods, it is believed that commercially available assay 
kit is more reliable as chemicals and reagents are already prepared of required concentrations. 
pH is sustained for reagents and for each pack. Finished ready to use substrate, buffers, 
accelerator and inhibitors are available in same kit and only few steps are required to get 
results making it easier to perform the experiment. Whereas for in-house assay method, one 
needs to prepare all solutions and reagents before performing experiment of required 
concentrations and pH. Stability of pH is difficult to obtain depending upon storage 
conditions, and human errors e.g. (weighing, pippeting and handling errors, missing / addition 
of any ingredient, environmental contamination, temperature variations etc). Lots of the steps 
are involved from A- Z for each experiment to get results making it complicated. 
Precision and accuracy of results: 
Precision and accuracy of results is core for any study and votes for method of choice to 
perform experiments and helps to draw the conclusion. In current study the results obtained 
from in-house ATPase assay method were more accurate and precise. Sensitive design of the 
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commercial kit could not get extra advantage although all the reagents were packed and 
sealed in small quantities sufficient for once use, keeping it safe from decaying or 
contaminating. But careful preparation of all reagents and solutions, proper pippeting 
technique, avoiding maximum possible human errors, best storage conditions, pH stability 
and favorable environmental conditions maintained during In-house ATPase assay procedure 
provided best reaction conditions for maximum ATPase activity, resulting in more precise 
measurements in contrast to commercial ATPase assay.  
Time to get result: 
During any scientific work the time used to get significant results is also important factor and 
aids for a valuable conclusion. In present scientific work done for measuring, cyclic 
nucleotide dependent ATPase activity in IOV of hRBC by In-house designed ATPase assay 
method it took almost continuous seven hours to get significant values for each set of 
experiment as compared to 3 - 4 hours used for measuring ATPase activity of IOV from 
hRBC while stimulating with cGMP by commercially available Innova Biosciences ATPase 
assay kit.  
Cost  
Economy is a key factor for method of choice for any scientific work. In-house assay method 
for measuring ATPase activity is highly cost effective. Almost all chemicals to make 
solutions and reagents are easily available in bulks in labs and one can prepare solutions of 
choice in good quantity and in good price comparing with commercially available kit which is 
rather expensive. 
Others: 
Effective scientific method is always reproducible. This key factor is a big support for in-
house method designed to measure ATPase activity of IOV from hRBC. To repeat the 
experiment in case of spillage or as per need is quite easy and possible. The availability of 
required information about all the chemicals and reagents and complete protocol to prepare 
solutions and buffers made it possible to reproduce it any time and in any part of the world, if 
you do not have access to commercially available ATPase assay kit of Innova Biosciences 
and can justify experimental findings. 
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Summarizing, for an analysis, using commercially available ATPase kit by Innova 
Biosciences is comparative expensive but this assay technique is time saving and easy to use. 
In-house ATPase assay method is not only cost effective but also has good reproducibility 
although takes little longer time than commercial assay kit. This assay method is not limited 
as in case of future investigations, modification could be made by addition or removal of any 



















5.  Conclusions: 
Present study was conducted to measure, “Cyclic nucleotide dependent ATPase activity in 
inside out vesicles from human erythrocytes”  y an in-house assay method and to compare it 
with commercial ATPase assay kit to make a cost benefit analysis.  
Present data obtained from experimental work shows that we have been able to design an 
assay method to measure cGMP dependent ATPase activity as an in-house assay method and 
we also compared it with commercially available ATPase assay kit by Innova Biosciences. 
 
The main findings were: 
 1) The inorganic phosphate standard curves were linear for relevant biological 
concentrations, observed for both in-house and commercial assay.  
2) The membrane protein (i.e. IOV) concentrations raised the inorganic phosphate 
concentrations linearly. 
 3) It was possible to distinguish cGMP-stimulated activity from basal ATPase activity in 
hRBC IOV, even though the difference was small.  
4) The two phosphate assays (in-house and commercial) had both advantages and 
disadvantages, none being superior to the other one. 
5.1.  Future directions:  
A scientific work always leaves open doors behind for new findings. So it is in this case as 
well. Some proposals for future investigations of cyclic nucleotide dependent ATPase activity 
in inside out vesicles from human erythrocytes could be,  
 Use different incubation time (longer or shorter). 
 By stimulating with different concentrations of cGMP less than 10µM. 
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 7.1. List of chemicals: 
 
    Description Components Notes (store at 4ºC if 

















Potassium hydroxide. Store in plastic bottle, 






















Gives pH =7.50  
 






≈ saturated, keep at 
room temp. 
 
ATP Na2ATP Keep ice cold on bench, 
store at  
-70°C 
 
 Phosphate, basic Na2HPO4•2H2O  
 
Phosphate, acidic NaH2PO4•H2O  
 





HCl (acid) 37 % Hydrochloric acid P = 1.184 g/ml 
 





Protease inhibitor cocktail 
 
SigmaP2714  







store in glass bottle, 
dark & cool in inert N2-
atmosphere 
 
NAD  β-Nicotinamide adenine 
dinucleotide 
 Keep ice cold on bench, 






 Keep ice cold on bench, 








   Sigma D 2158 
G-3-P Glyceraldehyd-3-phosphate Keep ice cold on bench, 
store at 










Store in cooling room. 
 
Tris concentrated, acidic Tris•HCl Store in cooling room. 
 
Potassium phosphate, acidic 
 
KH2PO4  





Keep ice cold on bench, 
store at        s-70°C. 
Sodium dodecyl sulphate Sodium dodecyl sulphate  
 


























7.2. Buffers and solutions: 
 





Final molarity of 
main components 
Notes (store at 
4ºC if not  
otherwise 
noted) 
NK NaCl 29.22 g NaCl 100 NaCl     5000 ≈ saturated, 
keep at room 
temp. 
 
KK KCl 29.82 g KCl 100 KCl        4000 ≈ saturated, 
keep at room 
temp. 
 
KOH KOH 28.06 g KOH 100 KOH      5000 Store in plastic 













100 EGTA      200 
 















200 HEPES   1000 
 
K+                  464 
 
Gives pH =7.50  
 




5.083 g MgCl2•6H2O 25 MgCl2      1000 ≈ saturated, 
keep at room 
temp. 
 
ATP ATP 3.31 g Na2ATP 20 NA2ATP  300 Keep ice cold 
on bench, store 
at -70°C 
 






1000 HEPES   10 
K+             8.6 
EGTA       2 
NaCl     150 
pH = 7.50 
 
L1 Lysis buffer # 1   5000 µl 
  4000 µl 






2000 EGTA        0.5 
MgCl2            2.0 
NA2ATP    0.6 
HEPES   20.0 
K+           28.9 
pH = 7.50 
L2 Lysis buffer # 2   5000 µl 




2000 EGTA         0.5 
HEPES    20 
K+            28.9 
 
pH = 7.50 
FB  Phosphate, basic 89.00 g Na2HPO4•2H2O 1000 Phosphate 500 
 
 
FS Phosphate, acidic 13.80 g NaH2PO4•H2O 500 Phosphate 200  
 
AK Arsenate 15.60 g Na2HAsO4•7H2O 
 
 





















HCl         1000 
 
 
P = 1.184 g/ml 
NOH NaOH (base) 0.200 g Sodium hydroxide 
 










Use as is 







100 Cysteine     5 
 
pH = 8.40 
 store in glass 
bottle, dark & 
cool in inert N2-
atmosphere 
 









 NAD            20 
 
 Keep ice cold 
on bench, store 
at -70°C. 
 






 ATCC      12.5  Keep ice cold 















50 DTNB         0.7 
 
Phosphate  100 
pH = 7.50 





 NAD           7.5 Keep ice cold 
on bench, store 
at 
 -70ºC. 
T5 Density # 5 28.27 g 
1424  µl 
1430  µl 





100 Phosphate  10 
 
Histodenz  28.27% 
pH = 7.50 
p =1.150 
Histodenz;  







phosphate       294 
 
Keep ice cold 
on bench, store 
at -70ºC. 








204   µl 









phosphate      15 
 
pH = 7.00 
Keep ice cold 














1000 Phosphate     10 
NaCl             137 
KCl                2.7 








 3750 µl 
  1500 µl 










Arsenate           30 
 
 





  7500 µl 




50 Pyrophosphate 30 pH = 8.40 
A Arsenate solution   4000 µl 
 
AK 10 Arsenate      400 Poisonous 
T4 Density #4   5580 µl 
    420 µl 
T5 
PBS 
 Histodenz  26.3% pH = 7.40 




Density # 3 
   
5170 µl 





Histodenz   24.3% 
 
pH = 7.40 







Density # 2 
   
4750 µl 






Histodenz   22.4% 
 
pH = 7.40 
p = 1.120 
T1 Density #1 21670 µl 




 Histodenz   20.4% pH = 7.40 
p = 1.110 
 
T0 Density #0 11750 µl 




 Histodenz   18.5% pH = 7.40 
p = 1.100 
 
F0 Phosphate buffer 
with 0 detergent 
    125 µl 




50 Phosphate       5 pH = 8.00 
 
FX Phosphate buffer 
with Triton X-100 
25000 µl 
      50 µl 
F0 
Triton X-100 
 Phosphate       5 
Triton X-100  0.2% 
 






for sidedness 1 
  2150 µl 
14000 µl 
    600 µl 










pH = 8.40 
 
IV0 Inside out vesicles 
with 0 detergent 
     55µl 




   
IVX Inside out vesicles 
with Triton X-100 
     55 µl 





















7.3. Sodium-free buffers and solutions: 
 




Final molarity of 
main components 
Notes (store at 4ºC if 













KOH         5000 
 
 
Store in tightly closed 
plastic bottle, as KOH 
will etch glass.  
 
KK KCl 29.82 g 
 
KCl 100 KCl           4000 Must be stored in room 
temperature, not in 
cooling room, as 







39.41 g Tris•HCl 250 Tris•HCl    1000 Store in cooling room. 








22.823g K2HPO4•3H2O 100 Phosphate   1000  
KPBS PBS where K+ is 
cation. 
  1471 µl 








Phosphate    9.57  
K+              157.7 




EGTA, neutral 6.168 g 
8000  µl 
     
EGTA 
KOH 
100 K2-EGTA    200 Store in cooling room 
PA 
 
Prep-buffer A   2880 µl 
  2120 µl 
28260 µl 







Tris                5 
K+               113 
Cl-               116 
 






   
2640 µl 
  2360 µl 
  2500 µl 











Tris                5 
EGTA            0.5 
K+                  4 
Cl-                  5.6 
 
pH = 8.1 
 
PC Prep-buffer C     202 µl 






Tris                0.5 
Cl-                   0.2 
 







     
264 µl 
    236 µl 
      75 µl 
    150 µl 











Tris                 5 
K+                   3.6 
Cl-                   5.6 
EGTA             0.3 
Histodenz   336 
 
pH = 8.1 
 




Prep- buffer E 
   
  292 µl 
    208 µl 
    150 µl 










Tris                 5 
K+               173 
Cl-               175 
EGTA            0.3 
 
pH = 8.1 
 









     
 667µl 





Tris                 5 
K+                117 
Cl-                119 
EGTA             0.3 
Histodenz   112 
 
 
pH = 8.1 
 
Density = 1.048g/ml 
 
GT2 Density gradient 
#2 
  4000 µl 




 Tris                 5 
K+                  60 
Cl-                  62 
EGTA             0.3 
Histodenz   224 
 
pH = 8.1 
 
Density = 1.097g/ml 
 
GT3 Density gradient 
#3 
  1500 µl 
      
 
PHIS  Tris                 5 
K+                   3.6 
Cl-                   5.6 
EGTA             0.3 
Histodenz   336 
 
 
pH = 8.1 
 
Density = 1.146g/ml 
 




25 MgCl2         1000  
MGF MgCl2 diluted     420 µl 
    980 µl 
MG 
Water 
 MgCl2          300  
ATP ATP-magnisum 
salt 
1.522 g Mg-ATP 10 Mg-ATP      300 Unstable, to be kept 
frozen or on ice for a 
minimum time. 
 
CG cGMP  0.00863 g 




















7.4. Solutions for ATPase assay for IOV: 
 




Final molarity of 
main components 
Notes (store at 4ºC 
if not  otherwise 
noted) 
KOH KOH 28.06 g 
 
KOH 100 KOH         5000 
 
Store in tightly 
closed plastic bottle, 
as KOH will etch 
glass. 
 
KK KCl 29.82 g 
 
KCl 100 KCl           4000 Must be stored in 
room temperature, 
not in cooling room, 
as solution is near 
saturation point. 
 
TS Tris, concentrated, 
acidic 
 
39.41 g Tris•HCl 250 Tris•HCl    1000 Store in cooling 
room. 




EGTA, neutral 6.168 g 
8000  µl 
     
EGTA 
KOH 




1.522 g Mg-ATP 10 Mg-ATP      300 Unstable, to be kept 
frozen or on ice for 
a minimum time. 
 
SDS Sodium dodecyl 
sulphate 





sulphate        12% 
 
 
OUA  Ouabain 0.29235 g g-strophanthin 
  
C29H44O12 
  5 Ouabain      100%  Very Poisonous!! 
 
Store in freezer. 
See important note 




Reagent B     3.00 g 
  7.395 g 
    
Ascorbic acid 




Ascorbat         6%                 
HCl            1500 
Dangerous!! 
See important note 
2 at bottom. 
 









molybdate     1 % 
See important note 





Reagent  BC 
    
 15000 µl 








Ascorbate      3%         
HCl             700 
 
Ammonium 
molybdate    0.5% 
 
See important note 
4 on bottom. 
 
CG cGMP  0.00863 g 




 cGMP       5  Store in freezer. 
CGD cGMP, diluted     600 µl 








cGMP     0.300 Store in freezer. 
CG3 cGMP, diluted   3000 µl 
  7000 µl 











solution # 0 
(basis) 
     
1.2 µl 
    85.7 µl 
    73.5 µl 
    98    µl 
  147    µl 
  510    µl 











Tris          51.72 
EGTA        5.175 
ATP         10.35 
Mg2+        10.35 
Ouabain     5.175 
K+           728.6 
cl-              39.8 
 
 
Total volume = 
          2840 µl 
 
Will be sufficient 
for 56 incubations 
when made into 
IQ1 and IQ2. 







solution # 1 (with 
cGMP) 
 
1400    µl 
    48.3 µl 





Tris          50.0 
EGTA        5.00 
ATP         10.0 
Mg2+        10.0 
Ouabain     5.00 
K+           704.3 
cl-            715.1 
cGMP         0.050 
 
 
Total volume = 
         1448 µl 
 
Will be sufficient 
for 28 incubations. 







solution # 2 
(without cGMP) 
   
1400  µl 






Tris          50.0 
EGTA        5.00 
ATP         10.0 
Mg2+        10.0 
Ouabain     5.00 
K+           704.3 
cl-            715.1 
cGMP         0.0 
 
 
Total volume = 
         1448 µl 
 
Will be sufficient 
for 28 incubations. 





Final incubate  # 1  
 
 
    
    50 µl 
  150 µl 
 
 
     
 
 












Tris         10.0 
EGTA        1.00 
ATP           2.0 
Mg2+          2.0 
Ouabain     1.00 
K+           140.9 
cl-            143.0 
cGMP         0.010 
 
  








Final incubate # 2 
 
 
     
  50 µl 
150 µl 
     
 
 
   
 











Tris         10.0 
EGTA        1.00 
ATP           2.0 
Mg2+          2.0 
Ouabain     1.00 
K+           140.9 
cl-            143.0 
cGMP         0.0 
  
 









Wear protective gloves and a mask to prevent inhaling of dust when weighing Ouabain. 
Note2: 
HCl is very volatile and corrosive, and will  urn skin. Use gloves. Don’t inhale vapor. Use 




RC must be allowed to stand and equilibrate for at least two hours before being mixed with 
RB to form the color developing BC reagent. This is important, since the dissolved 
ammonium molybdate requires time to reach the equilibrium point that exists between the 
various molybdate complexes that characterize the solution. Failure in allowing sufficient 
time for equilibrium to occur has led to inconsistencies in the results obtained thereafter. 
Note 4: 
 The stability and purity of this color reagent can then be tested spectrophotometricaly. It 
should give a reading of 0.052 units of optical density when measured at 680nm or 0.057- 
0.058 at 820nm. These values should remain constant over many hours. If they begin 




















7.5. Detailed Procedure of individual experiment 
7.5.1. Preparation of IOV from human erythrocytes 
 
This procedure must be done at 0 - 4°C, preferably in a cooling room, and yields a suspension 
of sealed IOV (and sealed ROV) void of any free phosphate. Tubes must always be carried on 
ice when transported between rooms. 
 
01. Blood is withdrawn into EDTA-tubes. 20 ml is equivalent to one gradient tube later in 
this procedure, at step 19. 
02. Centrifuge blood at 1000 g (2200 RPM) in original tubes for 15 minutes with max 
acceleration and max breaks. 
03. Plasma and buffy coat are carefully removed with a disposable pasteur pipette and 
wasted. 
04. Resuspend each 10 ml of packed erythrocytes in solution PA in a 50 ml centrifuge 
tube with round bottom. Do not fill the tube above the engraved line (ca 36 ml) on the 
tube. 
05. Centrifuge tubes in a Beckman centrifuge at 1000 g (2875 RPM with rotor JA 25.50) 
for 10 minutes with max acceleration and slow breaks. 
06. Supernatant is carefully removed and wasted. Also remove any remnants of a buffy 
coat. Repeat steps 4-6 two times more. 
07. Lyse cells by quickly adding 10 volumes of ice cold solution PB to the erythrocytes. 
Transfer the lysate to a flask. Mix and resuspend the suspension vigorously. Use a 
disposable pasteur pipette to detach and resuspend remnants that still adheres to the 
tube wall/bottom. Pour lysate into tubes suited for centrifuge rotor JA-18. Make sure 
that the gasket of the tubes is mounted and the lid is tightly screwed on. 
08. Centrifuge tubes in a Beckman centrifuge at 20000 g (11600 RPM with rotor JA-18) 
for 20 minutes with max acceleration and with breaks off. Because of the lack of 
breaks it will take ca 60-75 minutes (depending on number of tubes) before the 
centrifuge comes to a complete halt. When placing the tubes in a container filled with 
ice for transport between rooms, position the tube in such a way that it is impossible 
for the fluffy ghost sediment at the bottom of the tube to slide in any direction. This is 




09. Supernatant is carefully removed and wasted with an electrical high volume capacity 
pipette. Be careful not to touch any of the fluffy ghost (RBC membranes) sediment at 
the bottom of the tube. Switch to a disposable pasteur pipette for the delicate work of 
removing the last remnants of the supernatant. 
10. After the first centrifugation post lysis, pour the ghost suspension to another clean 
centrifugation tube without removing the small hard yellowish pellet that is seen on 
the lower tube wall. The pellet is believed to contain contaminating proteases. After 
pouring, put tube in an upright position and wait a minute for the remaining viscous 
ghost suspension to slide down from the walls to gather at the bottom of the tube and 
then collect it carefully with a disposable pasteur pipette. Do not disturb the pellet. If 
traces of a yellowish pellet are seen in subsequent centrifugation steps, transfer ghost 
suspension to another clean tube as described. 
11. Resuspend the ghosts in solution PB. 
12. Centrifuge tubes in a Beckman centrifuge at 20000 g (11600 RPM with rotor JA-18) 
for 15 minutes with max acceleration and with slow breaks. Total centrifugation time 
is ca 25 minutes. 
13. Be careful to remove all supernatant. 
14. Repeat step 11-13 until the ghosts are milky white. It is important that all remnants of 
the supernatant consisting of solution PB is removed before proceeding to step 15, as 
a high ion concentration of ions surrounding the ghosts has a negative influence on the 
yield of sealed inside-out vesicles. 
15. Measure the total volume of ghost suspension with a large pipette. Mix the ghosts 
with 50 volumes of solution PC and incubate the suspension for at least 2 hours to 
favor vesiculation. 
16. Distribute the suspension in tubes suited for centrifuge rotor JA-18. The tubes must be 
of pair-wise equal weight to an accuracy of 2/100 of a gram for centrifugation balance 
in the next step. This is a general rule throughout the rest of this procedure for tubes 
that are to be centrifuged at high speeds. 
17. Place tube pairs of equal weight diametrically opposed to each other in a Beckman 
centrifuge and centrifuge them at 47900 g (18000 RPM with rotor JA-18) for 30 
minutes with max acceleration and with slow breaks. 




19. Collect the membrane pellet with a disposable pasteur pipette by resuspending the 
pellet of the second tube in the pellet suspension collected from the first tube, and so 
on. Remnants are collected by washing the tube bottoms with a small amount of 
solution PC. 
20. Homogenize the membrane pellet by forcing the suspension slowly both up and down 
through a 27” gauge cannula with the aid of a 1 ml syringe. Repeat this 5 times. If a 
very large volume of suspension is to be homogenized, use several syringes in 
parallel, bundled together with some tape. 
21. The homogenate is applied on top of a Histodenz gradient tube (ca 2 ml for each 
tube). The tubes must be of pair wise equal weight to an accuracy of 2/100 of a gram 
for centrifugation balance in the next step. 
22. Centrifuge tubes in a Beckman ultra centrifuge at 100 000 g (23700 RPM with rotor 
SW40) for at least 1 hour, or conveniently over night, with slow acceleration and 
breaks off. Be careful to balance diametrically opposed tubes. 
23. Puncture the tube with a cannula and remove the upper band containing sealed IOV 
and sealed ROV with aid of a syringe. The lower band contains unsealed vesicles / 
ghosts of no interest. The tubes can be discarded. 
24. Remove most of the Histodenz by resuspending the IOV in 100 volumes of solution 
PC, and centrifuge tubes in a Beckman centrifuge at 47900 g (18000 RPM with rotor 
JA-18) for 30 minutes with max acceleration and slow breaks. 
25. Remove supernatant and collect pellet. Remnants of IOV are collected by washing the 
tube bottoms with a small amount of solution PC. 
26. Switch on spectrophotometer in time and do sidedness test on IOV. 
 
Sidedness Test of IOV of hRBC:  
The enzyme acetylcholinesterase (AChE) is anchored to the cell membrane and is located at 
the intra- and the extracellular side of the membrane. For the inside out vesicles the situation 
is the opposite. By measuring the activity of this enzyme at the extravesicular side, the 
relative size of the IOV- and ROV-fractions of the vesicles can be found. 
Example: IOV should give low AChE-activity, while ROV should give high AChE-activity. 
The detergent Triton-X100 will make the membrane leaky. In the presence of this detergent, 
any extravesicular substrate will also become available for intravesicular enzyme; then both 
59 
 
IOV and ROV will give high AChE-activity. Therefore, if vesicles of unknown sidedness 
show low AChE-activity without detergent, but show high GAPD-activity in the presence of 
detergent, this would indicate that the vesicles are IOV. 
1. You must need the solutions IS2, IV0, IVX, and ATCC. 
IS2 must be at room temperature while the other solutions are incubated on ice > 1 
min before use. 
2. In to a 1ml quartz cuvett, mix well in this order: 920 µl IS2 + 20µl IV0 + 63 µl ATCC 
(starts reaction), set reference to zero absorbance at 412 nm. 
3. The increase in absorbance in 1 and 3 minutes is measured. 
4. Repeat step 2 - 3 for a total of three parallels. 


















7.5.2. Phosphate assay and different phosphate concentrations 
 
Different concentrations of phosphates (5  M,15  M, 25  M, 50  M, 100  M and 250  M) 
were prepared and  in the presence of cGMP are incu ated for suggested time in a solution 
with pH  .0 at 37  C that optimizes transport activity for the assay. Reaction was stopped by 
using SDS 12%. Addition of coloring reagent made a color complex with free phosphates. 
Absorbance of analytes measured was directly proportional to the amount of available 
inorganic phosphates. 
Procedure: 
1. Use microcentrifuge tubes with snap cap. 
2. Make IQ1 and IQ2 and keep them in water  ath at 37  C 
3. Make FIQ1 by mixing 50µl IQ1 with 150 µl phosphate solution of known concentrations, 
and finally 50µl water. Total volume is 250 µl 
4. Make FIQ2 by mixing 50µl IQ2 with 150 µl phosphate solution of known concentrations, 
and finally 50µl water. 250 µl 
5. Incu ate  I 1 and  I 2 for 60 minutes at 37  C in a waterbath. 
6. Stop reaction by adding 150 µl SDS. Be careful to not froth up the solution when adding 
the detergent. 
7. Cool the tubes to room temperature for 5 minutes. 
8. Start the development of color by adding 600µl BC and mix well without making bubbles 
as the clock is started immediately. Final volume is 1ml. 











7.5.3. Phosphate assay and the effect of different concentrations of cGMP 
Different concentrations of cGMP (0.5 µM, 5 µM, 25 µM, 50 µM and 100 µM) and Same 
concentrations of phosphates (0.5 µM, 5 µM, 25 µM, 50 µM and100 µM) were prepared and, 
in the absence of cGMP are incubated for suggested time in a solution with pH  .0 at 37  C 
that optimizes transport activity for the assay. Volume of cGMP was replaced with water. 
Reaction was stopped by using SDS 12%. Addition of coloring reagent made a color complex 
with free phosphates. Absorbance of analytes measured was directly proportional to the 
amount of available inorganic phosphates. 
Procedure: 
1. Use microcentrifuge tubes with snap cap. 
2. Make I 1 and I 2 and keep them in water  ath at 37  C 
3. Make different concentrations of cGMP (0.5 µM, 5 µM, 25 µM, 50 µM and 100 µM). 
4. Make different concentrations of phosphate solution (0.5 µM, 5 µM, 25 µM, 50 µM and 
100 µM). 
5. Make FIQ1 by mixing 50µl IQ1 with 150 µl water, and finally 50 µl phosphate solution of 
known concentration. Final volume is 250 µl. 
6. Make FIQ2 by mixing 50µl IQ1 with 150 µl water, and finally 50 µl of different 
concentrations of cGMP.  Final volume is 250 µl. 
7.  Repeat the step 5 and 6 for each concentration of Phosphate solution and cGMP solution. 
8. Incu ate  I 1 and  I 2 for 60 minutes at 37  C in a water bath. 
9. Stop reaction by adding 150 µl SDS. Be careful to not froth up the solution when adding 
the detergent. 
10. Cool tubes to room temperature for 5 minutes. 
11. Start the development of color by adding 600 µl BC and mix well without making bubbles 
as the clock is started immediately. Final volume is 1ml. 







7.5.4. Phosphate assay of IOV in presence and absence of cGMP 
  
Inside out vesicles of hRBCs were stored at -70 C in microcentrifuge tubes. Required 
numbers of tubes was taken out of freezer and were kept in ice box at    C. The thawn vesicle 
suspension was used to prepare analytes. These analytes of IOV suspension were added in the 
presence of cGMP to a solution with pH  .0 at 37  C that optimizes transport activity are 
incubated for suggested time. The transport reaction starts when IOV are mixed in. Reaction 
was stopped by using SDS 12%. Addition of coloring reagent made a color complex with free 
phosphates. Absorbance of analytes measured was directly proportional to the amount of 




1. Use microcentrifuge tubes with snap cap. 
2.  Make I 1 and I 2 and keep them in water  ath at 37  C 
3. Thaw I  s and keep them in ice  ox at    C 
4. Make FIQ1 by mixing 50 µl IQ1 with 150 µl water, and finally 50 µl vesicle suspensions. 
Final volume is 250µl. 
5. Make FIQ2 by mixing 50 µl IQ2 with 150 µl water, and finally 50 µl vesicles suspension. 
Final volume is 250µl. 
6. Incu ate  I 1 and  I 2 for 60 minutes at 37  C in a water bath. 
7. Stop reaction by adding 150 µl SDS. Be careful to not froth up the solution when adding 
the detergent. 
8. Cool tubes to room temperature for 5 minutes. 
9. Start the development of color by adding 600 µl BC and mix well without making 
bubbles as the clock is started immediately. Final volume is 1ml. 






7.5.5.  Effect of different IOV concentrations on ATPase assay 
Inside out vesicles of hRBCs were stored at -70 C in microcentrifuge tubes. Required 
numbers of tubes was taken out of freezer and were kept in ice box at    C. The thawn vesicle 
suspension was used to prepare different dilutions of IOV  25 , 50 , 75 , and 100 ). 
These concentrations of I   suspension were added in the presence of cGMP in a solution 
with pH  .0 at 37  C that optimizes transport activity are incubated for suggested time for the 
assay. The transport reaction starts when IOV are mixed in. Reaction was stopped by using 
SDS 12%. Addition of coloring reagent made a color complex with free phosphates. 
Absorbance of analytes measured was directly proportional to the amount of available 
inorganic phosphate. 
Procedure: 
1. Use microcentrifuge tubes with snap cap. 
2. Make I 1 and I 2 and keep them in water  ath at 37  C 
3. Thaw I  s and keep them in ice  ox at    C. 
4. Prepare different dilution concentrations of IOV suspension (Vesicles Dilution Series, 
25%, 50%, 75%, and 100%). 
5. Make FIQ1 by mixing 50µl IQ1 with 150 µl water, and finally 50 µl vesicle 
suspension of required concentration. Final volume is 250 µl. 
6. Make FIQ2 by mixing 50 µl IQ2 with 150 µl water, and finally 50 µl vesicles 
suspension of required concentration. Final volume is 250 µl. 
7. Repeat the step 5 and 6 for all different dilution concentrations of IOV suspension. 
8. Incu ate  I 1 and  I 2 for 60 minutes at 37  C in a water bath. 
9. Stop reaction by adding 150 µl SDS. Be careful to not froth up the solution when 
adding the detergent. 
10. Cool tubes to room temperature for 5 minutes. 
11. Start the development of color by adding 600 µl BC and mix well without making 
bubbles as the clock is started immediately. Final volume is 1ml. 







7.5.6. Difference in absorbance in presence and absence of IOV  
 
Inside out vesicles of human erythrocytes were stored at -70 C in microcentrifuge tubes. 
Required numbers of tubes was taken out of freezer and were kept in ice box at    C. The 
thawn IOV were added in the a sence of cGMP in a solution with pH  .0 at 37  C that 
optimizes transport activity are incubated for suggested time for the assay. The transport 
reaction starts when IOV are mixed in. Reaction was stopped by using SDS 12%. Addition of 
coloring reagent made a color complex with free phosphates. Absorbance of analytes 
measured was directly proportional to the amount of available inorganic phosphates. 
 
Procedure: 
1. Use microcentrifuge tubes with snap cap. 
2. Make I 2 and keep it in water  ath at 37  C 
3. Thaw I  s and keep them in ice  ox at    C. 
4. Make FIQ1 by mixing 50 µl IQ2 with 150 µl water, and finally 50 µl vesicle suspensions. 
Final volume is 250 µl. 
5. Make FIQ2 by mixing 50 µl IQ2 with 200 µl water. Final volume is 250 µl. 
6. Incu ate  I 1 and  I 2 for 60 minutes at 37  C in a water bath. 
7. Stop reaction by adding 150 µl SDS. Be careful to not froth up the solution when adding 
the detergent. 
8. Cool tubes to room temperature for 5 minutes. 
9. Start the development of color by adding 600 µl BC and mix well without making 
bubbles as the clock is started immediately. Final volume is 1ml. 








7.5.7.  ATPase assay with higher  IOV concentrations  
Inside out vesicles of hRBC were stored at -70 C in microcentrifuge tubes. Six tubes were 
taken out of freezer and were kept in ice box at    C. The thawn vesicle suspension was six 
times concentrated by using centrifuge. This concentrated suspension was used to prepare 
different dilutions of IOV  y adding water  25 , 50 , 75 , and 100 ). These 
concentrations of I   suspension were added in the presence of cGMP in a solution with pH 
 .0 at 37  C that optimizes transport activity are incubated for suggested time for the assay. 
The transport reaction starts when IOV are mixed in. Reaction was stopped by using SDS 
12%. Addition of coloring reagent made a color complex with free phosphates. Absorbance of 
analytes measured was directly proportional to the amount of available inorganic phosphates. 
Procedure: 
1. Use microcentrifuge tubes with snap cap. 
2. Make I 1 and I 2 and keep them in water  ath at 37  C 
3. Take 6 ml I   suspension, thaw them and concentrate it to 1ml  y centrifugation. 
Keep it in ice  ox at    C. 
4. Prepare different dilution concentrations from this 6 times concentrated IOV 
suspension (Vesicles Dilution Series, 25%, 50%, 75%, and 100%). 
5. Make FIQ1 by mixing 50 µl IQ1 with 150µl water, and finally 50 µl vesicle 
suspension of required concentration. Final volume is 250 µl. 
6. Make FIQ2 by mixing 50 µl IQ2 with 150 µl water, and finally 50 µl vesicles 
suspension of required concentration. Final volume is 250 µl. 
7. Repeat the step 5 and 6 for each concentration of IOV suspension. 
8. Incubate FIQ1 and FIQ2 for 60 minutes at 37  C in a water bath. 
9. Stop reaction by adding 150 µl SDS. Be careful to not froth up the solution when 
adding the detergent. 
10. Cool tubes to room temperature for 5 minutes. 
11. Start the development of color by adding 600 µl BC and mix well without making 
bubbles as the clock is started immediately. Final volume is 1ml. 






7.5.8.  ATPase assay with higher IOV concentrations with modified protocol 
Six microcentrifuge tubes of IOV stored at -70  C were thawn and kept in ice box at    C. 
Concentrated the thawn vesicle suspension six times, by using centrifuge. From this 
concentrated IOV stock suspension further dilutions of (25%, 50%, 75%, and 100%) were 
made and incubated in a solution of pH 8.0, with and without cGMP at 37  C for 60 minutes 
that optimizes transport activity for the assay. The transport reaction starts when IOV are 
mixed in. Reaction was stopped and phospholipids were removed before incubation for color 
reaction. Color complex formation between coloring reagent and phosphates released gave 
absorbance which is directly proportional to the amount of available inorganic phosphates. 
Procedure: 
1. Use microcentrifuge tubes with snap cap. 
2. Make IQ1 and IQ2 and keep them in water  ath at 37  C 
3. Take 6 ml I   suspension, thaw them and concentrate it to 1ml  y centrifugation. Keep it 
in ice  ox at    C. 
4. Prepare different dilution concentrations from this 6 times concentrated IOV suspension 
(Vesicles Dilution Series, 25%, 50%, 75%, and 100%). 
5. Make FIQ1 by mixing 50 µl IQ1 with 150 µl water, and finally 50 µl vesicle suspension 
of required concentration. Final volume is 250 µl. 
6. Make FIQ2 by mixing 50 µl IQ2 with 150 µl water, and finally 50 µl vesicles suspension 
of required concentration. Final volume is 250 µl. 
7. Repeat the step 5 and 6 for each concentration of IOV suspension. 
8. Incu ate  I 1 and  I 2 for 60 minutes at 37  C in a water bath. 
9. Stop reaction by chilling in ice cold water for 10 minutes. 
10. Centrifuge at 13000 RPM for 15 minutes. Remove the supernatant by not disturbing the 
vesicles pellets. 
11. Add 150 µl SDS. Be careful to not froth up the solution when adding the detergent and 
cool tubes to room temperature for 5 minutes. 
12. Start the development of color by adding 600 µl BC and mix well without making 
bubbles as the clock is started immediately. Final volume is 1ml. 





7.5.9. ATPase assay of IOV with commercial kit  
The ATPase colorimetric assay kit employs all reagents necessary for measuring ATPase 
activity. The kit contains PᵢColorLock™ Gold reagent  an improved malachite green 
formulation) with additives to prevent background signals arising out of non-enzymatic ATP 
hydrolysis. Assay can be read anywhere in the wavelength range 590- 660nm. 
Materials: 
 
                                            C): 
 
 1 X 10ml of PᵢColorLock™ Gold*      (1 X 25ml) 
 1 X 0.25ml of Accelerator                    (1 X 0.5ml) 
 1 X 5ml of stabilizer                             (1 X 10ml) 
 1 X 1.5ml of 0.1M MgCl2                     (2 X 1.5ml) 
 1 X 5ml of 0.5 M Tris pH 7.5               (1 X 10ml) 
 1 X 5ml of 0.1mM Pᵢ standard             (1 X 10 ml) 
 
                                         -    C): 
 
 2 X 1ml specially purified ATP             (5 X1ml) 
 
 Other components: 
 
 Inside out vesicles. 
 Water 
 10µM cGMP. 
 *Exercise caution – this reagent contains 5 M HCl. Wear gloves and safety glasses. 
Procedure: 
 
1.   Make without cGMP substrate / buffer mix. The assay kit is supplied with 0.5 M Tris 
assay buffer pH 7.4. Most ATPase will require a metal ion cofactor. MgCl2 (0.1M) is 
supplied with the kit. Table 1 (below) shows the volumes required to make up SB mix for 
selected no. of cuvettes. These volumes result in final buffer and Mg²
+ 
concentrations (i.e. 
after your enzyme has been added) of 50mM and 2.5 mM, respectively. The final 




No. of  
cuvettes 
0.5M Buffer  
     (µl) 
0.1M MgCl2 










    74.2 
 
    18.55 
 
   37.1 
 





  1038.8 
 
     259.7 
 
   519.4 
 
   3376.1 
 
2. Make with cGMP substrate / buffer mix. The assay kit is supplied with 0.5 M Tris assay 
buffer pH 7.4.    Most ATPase will require a metal ion cofactor. MgCl2 (0.1M) is supplied 
with the kit. Other then assay kit components, cGMP (10µM) was also provided to make 
with cGMP substrate / buffer mix. Table 2 (below) shows the volumes required to make 
up SB mix for selected no. of cuvettes. These volumes result in final buffer and Mg²
+ 
concentrations (i.e. after your enzyme has been added) of 50mM and 2.5 mM, 
respectively. The final concentration of purified ATP is 0.5mM. 
 
No. of  
cuvettes 
0.5M Buffer  
     (µl) 
0.1M 
MgCl2 












    74.2 
 
    18.55 
 
   37.1 
 







  1038.8 
 
     259.7 
 
   519.4 
 




3. Make ‘Gold mix’  y adding Accelerator to PᵢColor Lock™Gold. 
 
4. Prepare ‘Gold mix shortly before the reagent is required by adding 1/100 volume of 
Accelerator to PᵢColorLock™Gold  see table 3 below). 
 
No. Of Cuvettes 
 
  Pᵢ Color Lock™ 
        Gold (µl) 
   Accelerator 
       (µl) 
 
    1 
 
 
            185 
 
      1.85 
 
    14 
 
 
           2590 
 




5. Set up assays with ATPase (not supplied); 371µl vesicles plus 371µl substrate/buffer mix 
with cGMP and without cGMP.  y fixing the assay time 30 minutes, and temperature 25  
C.  
 
6. Stop reaction by chilling in ice cold water for 10 minutes. 
 
7. Centrifuge at 13000 RPM for 15 minutes. Remove the supernatants. 
 
8. Add 185µl of Gold mix to stop reactions. 
 
9. After 2 minutes, add 74 µl of stabilizer. 
 





















7.6. Results, raw data of individual experiment 
 
7.6.1. Results for sidedness test of IOV 
Three different batches of IOV were prepared and tested for sidedness, following yields were 
obtained. 
Table a. for batch 1: 
 
IV0 
   
Mean  IV0    
 
      IVX 
 
Mean  IVX 
0.86    
 
   0.93 
   1.80   
 
  1.86 
 
0.95    1.86 
0.99    1.92 
 
Table a contains mean value for IV0 (0.93) calculated by three times measured optical absorbance (OD) at 40 
minutes and the mean value for IVX (1.86) calculated by three times measured optical absorbance (OD) at 40 
minutes. 
Calculation of percentage of inside out vesicles  
  Percentage of right side out vesicles = IV0 
                                                                 IVX 
                                                          = 0.93 
                                                             1.86 
                                                          = 0.5 ~ 50% 
  Percentage of inside out vesicles      = 100 – ROV % age  
                                                           = 50 % 
After experiment 1 yield of Inside out vesicles was 50%. Total obtained volume of vesicles 
were distributed in 1mL aliquots, labeled them with percentage,  and stored at -70  C to reuse 






Table b. for batch 2: 
 
IV0 
   
  Mean  IV0    
 
      IVX 
 
   Mean  IVX 
0.890    
 
   0.892 
   1.191   
 
  1.195 
 
0.896    1.207 
0.889    1.189 
 
Table b  contains mean value for IV0 (0.892) calculated by three times measured optical absorbance (OD) at 40 
minutes and the mean value for IVX (1.195) calculated by three times measured optical absorbance (OD) at 40 
minutes. 
Calculation of percentage of IOV  
Percentage of right side out vesicles = IV0 
                                                          IVX 
                                                       = 0.892 
                                                           1.195 
                                                        = 0.74 ~ 74% 
 Percentage of inside out vesicles      = 100 – ROV % age  
                                                         = 26 %  
After experiment 2, yield of IOV was 26%. Total obtained volume of vesicles were 
distributed in 1mL aliquots, labeled them with percentage and stored at -70  C to reuse them as 
per required. 
Table c. for batch 3: 
 
IV0 
   
  Mean IV0    
 
      IVX 
 
   Mean IVX 
0.889    
 
   0.893 
   1.217   
 
  1.235 
 
0.896    1.207 
0.894    1.220 
 
Table c contains mean value for IV0 (0.893) calculated by three times measured optical absorbance (OD) at 40 




 Calculation of Percentage of IOV: 
 Percentage of right side out vesicles = IV0 
                                                         IVX 
 
                                                        = 0.893 
                                                           1.235 
                                                         = 0.72 ~ 72% 
    Percentage of inside out vesicles    = 100 – ROV % age  
                                                        = 28 % 
After experiment 3, yield of IOV was 28%. Total obtained volume of vesicles were 





















7.6.2. Effect of different IOV concentrations on ATPase assay: 
 
To verify the results, this experiment was performed three times according the same protocol 






                         Absorbance  
 








 a b c Mean  SD  a b c Mean  SD 
   
% SD  
25 0,08 0,08 0,082 0,081 0,0009 0,036 0,011 0,015 0,021 0,0110 58,82 0,011005 
 
50 0,082 0,08 0,096 0,086 0,0071 0,018 0,025 0,03 0,024 0,0049 60,78 0,008654 
 
75 0,096 0,09 0,094 0,093 0,0025 0,03 0,027 0,02 0,026 0,0042 65,68 0,004876 
 
100 0,104 0,103 0,099 0,102 0,0022 0,037 0,031 0,033 0,034 0,0025 66,66 








                         Absorbance  
 













25 0,039 0,031 0,039 0,036 0,0038 0,033 0,027 0,022 0,027 0,0045 6,52 0,005869 
 
50 0,058 0,061 0,065 0,061 0,0029 0,051 0,055 0,04 0,049 0,0063 8,69 0,00696 
 
75 0,089 0,089 0,07 0,083 0,0090 0,11 0,115 0,101 0,109 0,0058 -18.11 0,010667 
 











                                   Absorbance  
 








 a b c Mean SD  a b c Mean SD % 
 
SD 
25 0,034 0,037 0,036 0,036 0,036 0,036 0,029 0,029 0,031 0,0033 9,70 0,03637 
 
50 0,055 0,063 0,061 0,060 0,060 0,060 0,043 0,043 0,049 0,0082 11,65 0,061772 
 
75 0,07 0,086 0,077 0,078 0,078 0,078 0,061 0,061 0,067 0,0085 13,59 0,080667 
 
100 0,1 0,099 0,103 0,101 0,101 0,101 0,087 0,087 0,092 0,0065 14,56 0,101098 
 
Table (d, e and f) explains about absorbance (at 680nm) of different concentrations of IOV with and without 
cGMP, also the Percentage of difference of absorbance and standard deviations.  
To measure ATPase activity, for each IOV concentration e.g. (25%) three parallels with cGMP and three 
parallels for same IOV concentration but without cGMP were prepared to avoid possible errors. Absorbance 
measured at wavelength 680 nm for each parallel is presented by a, b, and c also calculated the mean and 
standard deviation for both (IOV concentration with and without cGMP).Percentage of difference of absorbance 














7.6.3. ATPase Assay with higher IOV concentrations 
To verify the results, this experiment was performed three times according the same protocol 







                         Absorbance  
 






 a b c 
 
Mean SD  a b c Mean SD %    SD 
25 0,023 0,019 0,013 0,018 0,0041 0,012 0,018 0,01 0,013 0,0034 5,31 0,005333 
 
50 0,038 0,034 0,038 0,037 0,0019 0,037 0,034 0,037 0,036 0,0014 1,06 0,002357 
 
75 0,068 0,072 0,059 0,066 0,0054 0,037 0,041 0,037 0,038 0,0019 29,78 0,005754 
 








                         Absorbance  
 
 






 a b c Mean SD  a b c 
 
Mean SD % SD 
25 0,228 0,222 0,22 0,223 0,0034 0,149 0,145 0,147 0,147 0,0016 80,85 0,003771 
 
50 0,242 0,249 0,24 0,244 0,0039 0,185 0,183 0,179 0,182 0,0025 65,95 0,004595 
 
75 0,273 0,276 0,272 0,274 0,0017 0,205 0,202 0,2 0,202 0,0021 76,59 0,002667 
 










                         Absorbance  
 
 






 a b c Mean SD  a b c Mean SD % 
 
 SD 
25 0,015 0,015 0,014 0,015 0,015 0,012 0,013 0,016 0,014 0,0017 1,69 0,014654 
 
50 0,031 0,03 0,027 0,029 0,029 0,027 0,022 0,015 0,021 0,0049 13,56 0,029196 
 
75 0,046 0,049 0,034 0,043 0,042 0,038 0,038 0,042 0,039 0,0019 6,78 0,042042 
 
100 0,059 0,062 0,057 0,059 0,059 0,052 0,054 0,056 0,054 0,0016 8,47 0,059467 
 
 
Table (g, h and i) shows absorbance (at 680 nm) of different concentrations of 6 X concentrated IOV with and 
without cGMP, also the Percentage of difference of absorbance and standard deviations.  
To measure ATPase activity, for each IOV concentration e.g. (25%) three parallels with cGMP and three 
parallels for same IOV concentration but without cGMP were prepared to avoid possible errors. Absorbance 
measured at wavelength 680 nm for each parallel is presented by a, b, and c also calculated the mean and 
standard deviation for both (IOV concentration with and without cGMP). Percentage of difference of absorbance 













7.6.4. ATPase Assay with higher IOV concentrations with modified protocol                
To verify the results, this experiment was performed three times according the same protocol 







                         Absorbance 
 
 








 a b c mean SD    a b c 
 
mean SD  %   SD 
25 0,08 0,08 0,082 0,081 0,0009 0,036 0,011 0,015 0,021 0,0110 58,82 0,011005 
 
50 0,082 0,08 0,096 0,086 0,0071 0,018 0,025 0,03 0,024 0,0049 60,78 0,008654 
 
75 0,096 0,09 0,094 0,093 0,0025 0,03 0,027 0,02 0,026 0,0042 65,68 0,004876 
 







                         Absorbance 
 
 








 a b c mean SD  a b c 
 
mean SD  %   SD 
25 0,039 0,031 0,039 0,036 0,0038 0,033 0,027 0,022 0,027 0,0045 7,5 0,005869 
 
50 0,058 0,061 0,065 0,061 0,0029 0,051 0,055 0,04 0,049 0,0063 10 0,00696 
 
75 0,110 0,115 0,101 0,109 0,0058 0,089 0,089 0,08 0,086 0,0042 19,16 0,00718 
 











                         Absorbance 
 
 








 a b c mean SD  a b c 
 
mean SD   %   SD 
25 0,034 0,037 0,036 0,036 0,036 0,027 0,029 0,023 0,026 0,0025 9,9 0,036308 
 
50 0,055 0,063 0,061 0,060 0,061 0,046 0,043 0,048 0,046 0,0021 13,86 0,061257 
 
75 0,07 0,086 0,077 0,078 0,080 0,064 0,061 0,064 0,063 0,0014 14,85 0,080235 
 
100 0,1 0,099 0,103 0,101 0,101 0,085 0,087 0,083 0,085 0,0016 15,84 0,100902 
 
Table (j, k and l) is about absorbance (at 680 nm) of 6 X concentrated IOV of different dilution concentrations 
with and without cGMP, also the difference of absorbance in percent and standard deviations with modified 
protocol for minimizing the presence of phospholipids. 
To measure ATPase activity, for each IOV concentration e.g. (25%) three parallels with cGMP and three 
parallels for same IOV concentration but without cGMP were prepared to avoid possible errors. Absorbance 
measured at wavelength 680 nm for each parallel is represented by a, b, and c also calculated the mean and 
standard deviation for both (IOV concentration with and without cGMP). Percentage of difference of absorbance 












7.6.4. ATPase assay of IOV with commercial kit  
To verify the results, this experiment was performed three times according the same protocol 







                         Absorbance 
 
 








 a b c mean SD  a b c mean SD % 
 
SD 
25 0,2 0,23 0,223 0,218 0,0128 0,047 0,036 0,04 0,041 0,0045 0,177 0,013597 
 
50 0,197 0,24 0,196 0,211 0,0205 0,004 0,029 0,067 0,033 0,0259 0,178 0,033039 
 
75 0,339 0,34 0,363 0,347 0,0111 0,135 0,137 0,151 0,141 0,0071 0,206 0,013174 
 







                         Absorbance 
 
 








 a b c mean SD  a b c mean 
 
SD  %   SD 
25 0,356 0,356 0,372 0,361 0,0075 0,349 0,377 0,326 0,351 0,0209 0,01 0,022176 
 
50 0,778 0,75 0,681 0,736 0,0408 0,73 0,733 0,71 0,724 0,0102 0,012 0,042021 
 
75 0,921 0,949 0,906 0,925 0,0178 0,875 0,877 0,881 0,878 0,0025 0,047 0,017994 
 












                         Absorbance 
 
 








 a b c mean SD  a b c 
 
mean SD  %   SD 
25 0,252 0,29 0,273 0,272 0,0155 0,236 0,208 0,219 0,221 0,0115 0,051 0,019345 
 
50 0,503 0,523 0,444 0,490 0,0335 0,437 0,437 0,44 0,438 0,0014 0,052 0,033566 
 
75 0,706 0,642 0,648 0,665 0,0289 0,624 0,603 0,608 0,612 0,0090 0,053 0,030218 
 
100 0,764 0,776 0,796 0,779 0,0132 0,72 0,72 0,716 0,719 0,0019 0,06 0,013333 
 
Table (m, n and o) shows absorbance (at 635 nm) of 6 X concentrated IOV of different dilution concentrations 
with and without cGMP, also the difference of absorbance in percent and standard deviations with Innova 
Biosciences ATPase assay kit. 
To measure ATPase activity, for each IOV concentration e.g. (25%) three parallels with cGMP and three 
parallels for same IOV concentration but without cGMP were prepared to avoid possible errors. Absorbance 
measured at wavelength 635 nm for each parallel is presented by a, b, and c also calculated the mean and 
standard deviation for both (IOV concentration with and without cGMP). Percentage of difference of absorbance 
was calculated by ((Mean with cGMP – Mean without cGMP) / Max. absorbance) x 100. 
 
 
 
 
 
 
 
 
